

Curriculum Vitae of Stephan Krähenbühl, MD, PhD

Basic information

- Place and date of birth: Langnau i.E., November 29, 1953
- Current address: Fischerweg 19, 4058 Basel
- Phone: 079 272 2537
- e-mail: Stephan.kraehenbuehl@usb.ch



Education and occupation

- 1968 - 1972: Gymnasium of Burgdorf, Berne, Switzerland
- 1972 - 1978: School of Pharmacy, University of Berne, Diploma 1978
- October 1978 - October 1980: Ph.D. thesis in Pharmaceutical Sciences in the Central Chemistry Laboratory, University Hospital of Berne (Prof. C. Bachmann/Prof. J.P. Colombo)
- 1979 - 1985: School of Medicine, University of Berne, Diploma 1985
- 1985: M.D. at the Institute of Clinical Pharmacology of the University of Berne (Prof. J. Reichen)
- January 1986: ECFMG, Berne
- 1981 - 1985: Head of the Hospital Pharmacy, Bezirksspital Niederbipp, Berne
- 1984 - 1989: Head of the Hospital Pharmacy, Bezirksspital Langnau, Berne
- January 1986 - December 1986: Internship, Department of Internal Medicine, Bezirksspital Langnau, Berne (H.R. Hunziker, M.D.)
- January 1987 - February 1989: Fellow, Institute of Clinical Pharmacology, University of Berne (Prof. J. Reichen/Prof. R. Preisig)
- March 1989 - March 1991: Fellow und Senior Fellow, Department for Clinical Pharmacology, Case Western Reserve University, Cleveland, Ohio 44106, USA (Prof. E.P. Brass/Prof. C.L. Hoppel)
- April 1991 - March 1993: Resident, Department of Internal Medicine, Inselspital, Berne (Prof. H. Studer and Prof. P.W. Straub)
- April 1993 - March 1997: Senior Physician, Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital, Zürich (Prof. P. Meier-Abt)
- October 1997 – December 1999: 1st Senior Physician, Clinical Pharmacology, University of Berne (Prof. J. Reichen and Prof. B.H. Lauterburg). Training in Clinical Pharmacology and in Hepatology
- October 1997 – December 1999: Senior Physician, Department of Internal Medicine, General Internal Medicine, Inselspital, Berne (Prof. W. Straub, Prof. F. Frey)
- January 2000 – June 2021: Head of the Division of Clinical Pharmacology & Toxicology at the University Hospital of Basel and of the Division of Clinical Pharmacology at the Department of Pharmaceutical Sciences (DPhS) of the University of Basel
- January 2002 – June 2002: Interimistic Head of Clinic B (Internal Medicine) of the University Hospital of Basel
- January 2003 – June 2021: Attending Chief Physician at the Clinics of Internal Medicine of the University Hospital of Basel
- January 2002 – today: President of the Medical Experts Committee (MEC) of the Swiss Drug Regulatory Authority (Swissmedic)
- March 2022 – today: Work part time (30%) in private practice PinMed in Wallisellen/Switzerland (internal medicine and clinical pharmacology)

- July 2023 – today: Work part time (30%) in Epatocentro Ticinese in Lugano/Switzerland (hepatology)

Professional Training

- April 1978: Swiss Federal Diploma in Pharmacy (University of Berne)
- November 1985: Swiss Medical Diploma (University of Berne)
- April 1993: Specialist for Internal Medicine (FMH)
- May 1994: Specialist for Clinical Pharmacology (FMH)
- October 1997: FAMH Title in Clinical Chemistry
- April 1997-December 1999: Training in Hepatology (there is no FMH title in Hepatology for non-gastroenterologists)

Scientific Training and Awards

- November 1981: PhD in Pharmaceutical Sciences (University of Berne), Thesis: "Entwicklung eines neuen Enzymassays für die N-Acetylglutamat-Synthetase: Bestimmung der Enzymaktivität in Geweben von Ratte und Mensch sowie Untersuchung der kinetischen Eigenschaften von menschlichem, aufgereinigtem Enzym."
- December 1985: MD (University of Berne), Thesis: "Defective bile acid transport in an animal model of defective debrisoquine hydroxylation."
- May 1988: Young Investigator Award of the American Gastroenterology Association (AGA) for: „Effect of secretin on bile formation in rats with cirrhosis of the liver: Structure-function relationship„
- November 1993: Venia Legendi in the fields of Internal Medicine and Clinical Pharmacology (University of Zürich): "Alterations in mitochondrial function and morphology in chronic liver disease: pathogenesis and potential for therapeutic intervention."
- October 1996: Special award of the Swiss Society of Gastroenterology and Hepatology (SGGH) for: „Reduced antioxidative capacity in liver mitochondria from bile duct ligated rats„
- October 1996: Special award of the Swiss Society of Gastroenterology and Hepatology (SGGH) for a poster presentation: „Der Benzoessäuremetabolismus ist ein Mass für die mitochondriale Funktion in cholestatichen Ratten„
- November 1997: Research award of the Swiss Society for Research in Surgery for: „Benzoic acid metabolism reflects hepatic mitochondrial function in rats with long-term extrahepatic cholestasis.“
- June 1998: Research award of the Swiss Society of Surgery for: „Rapid normalization of hepatic glycogen metabolism in rats with long-term bile duct ligation after biliodigestive anastomosis“
- September 1999: Professor for Clinical Pharmacology and Internal Medicine, University of Berne
- January 2000: Structural professorship for Clinical Pharmacology/Toxicology and Internal Medicine, University of Basel
- June 2005: Research award of the Swiss Society of Cardiology for: „Kinetics and dynamics of furosemide in healthy volunteers after oral or sublingual administration“
- November 2006: Poster prize of the Swiss Society of Pharmacology and Toxicology for the work: „PGC-1 α and MEF2 regulate the transcription of the organic cation and carnitine transporter OCTN2 in C2C12 cells“
- December 2008: Joint full professorship of the medical faculty and the faculty of natural sciences of the University of Basel

- October 2010: Annual price of the Swiss Society of Clinical Pharmacology and Therapeutics for the work: „Drug interactions with biotransformation and antiplatelet effect of clopidogrel in vitro” (published in Br J Pharmacol 2010;161:393-404)

Grants

Swiss National Science Foundation and other Foundations (competitive grants):

- March 1989 - February 1991: Grant of the Swiss National Science Foundation for a stay abroad 100'000 CHF
- January 1994 - December 1996: Swiss National Science Foundation (32-37280.93) 325'000 CHF
- February 1994: Foundation for Scientific Research at the University of Zürich 50'000 CHF
- January 1997 - March 2000: Swiss National Science Foundation (31-46792.96) 290'000 CHF
- January 1998 – December 2000: Swiss Research Foundation for Muscle Diseases 150'000 CHF
- April 2000 - March 2003: Swiss National Science Foundation (3100-059812.99/1) 225'000 CHF
- April 2002 – March 2003: Swiss Foundation for Aging 50'000 CHF
- April 2003 – March 2006: Swiss National Science Foundation (3100-059812.03/1) 200'000 CHF
- January 2004: Novartis Foundation 50'000 CHF
- April 2006 – March 2010: Swiss National Science Foundation (310000-112483/1) 300'000 CHF
- April 2010 – March 2014: Swiss National Science Foundation (31003A-132992/1) 397'000 CHF
- September 2010 – August 2013: ProDoc Swiss National Science Foundation 181'000 CHF
- April 2014 – December 2018: Swiss National Science Foundation (31003A_156270) 243'000 CHF
- April 2016 – March 2020: Swiss National Science Foundation (31003A_160206) 429'000 CHF (co-applicant, 200'000 CHF for my research group)

Industry and Associations:

- 2000 - 2020: Several grants from the Chemical and Pharmaceutical Industry (Astra-Zeneca, Braun, Novartis, Roche, RCC, Lonza) in total 2.5 Mio CHF for different research projects
- 2005: Important participation (initiation of the projects, pivotal input in the conducting of the projects) in the funding of two professorships in the Dept. of Pharmaceutical Sciences of the University of Basel (Novartis Chair in Mechanistic and Systemic Toxicology, Clinical Pharmacy & Pharmacoepidemiology). The value was approximately 3 Mio CHF.
- Since 2009: Main applicant for SCAHT (Swiss Center for Applied Human Toxicology) together with Prof. D. Hochstrasser of the University of Geneva. Yielded a total of approximately 35 Mio CHF for the years 2009-2021. This money was used for research, teaching and the toxicological information service. My research group was supported by approximately 2.5 Mio CHF 2009-2020.

Teaching

- January 87 - March 93: Lectures in Clinical Pharmacology for medical and pharmaceutical students at the University of Berne (1989/90 break due to a stay abroad)

- March 90 - March 91: Lectures and courses in Clinical Pharmacology for medical students at the Medical School of the Case Western Reserve University, Cleveland, Ohio, USA
- April 1993 - March 1997: Lectures in Clinical Pharmacology for medical, dental medicine and pharmaceutical students at the University of Zürich
- April 1994 - March 1997: Lectures in Hepatology for medical students at the University of Zürich
- April 1997- December 1999: Lectures in Clinical Pharmacology for medical and dental medicine students at the University of Berne
- April 1997 – December 1999: Group instructions for medical students (1st clinical year) at the University of Berne
- Since 2000: Lectures in Clinical Pharmacology for medical, dental medicine and pharmacy students at the University of Basel
- Since 2000: Lectures in basic and clinical toxicology for pharmacy students at the University of Basel
- Since 2000: Lectures in clinical nutrition for pharmacy students at the University of Basel
- Since 2000: Lectures in clinical nutrition at the Swiss Federal Technical Institute in Zurich
- 2011: Organization (together with Prof. A. Odermatt of the Dept. Pharmaceutical Sciences) of the new pregradual Master course „Toxicology“.

Supervision of Dissertations (PhD and MD theses)

Supervision of more than 40 dissertations at the Universities of Berne, Zurich and Basel.

Habilitations

- 2001: Dr. Christoph Meier, Medical Faculty, University of Basel
- 2003: Dr. Jörg Huwyler, Faculty of Natural Sciences, University of Basel
- 2005: Dr. Raymond Schlienger, Medical Faculty, University of Basel
- 2005: Dr. Christian Burri, Faculty of Natural Sciences, University of Basel
- 2005: Dr. Gabriele Weitz, Faculty of Natural Sciences, University of Basel
- 2006: Dr. Kurt Hersberger, Faculty of Natural Sciences, University of Basel
- 2009: Dr. Matthias Liechti, Medical Faculty, University of Basel
- 2011: Dr. Manuel Haschke, Medical Faculty, University of Basel
- 2016: Dr. Anne Leuppi-Taegtmeyer, Medical Faculty, University of Basel
- 2019: Dr. Jamal Bouitbir, Faculty of Natural Sciences, University of Basel
- 2021: Dr. Urs Duthaler, Faculty of Natural Sciences, University of Basel

Participation in Working Groups and Committees

- January 1994 - March 1996: President of the working group ‘medical subjects’ within the project „reformation of the studies in pharmacy“
- January 1995 - March 1997: Member of the Ethics Committee of the Department of Internal Medicine, University Hospital, Zürich
- October 1997 – December 1999: Member of the Consultation Committee in the field of clinical questions about nutrition, Inselspital, Berne
- January 1998 – December 1999: Member of the Ethics Committee, University of Berne, Medical School
- January 1999 – December 2001: External Advisor of the Swiss National Health Authorities (IKS), Berne
- Since January 2000: President of the Drug Surveillance Committee, University

- Hospital, Basel
- Since January 2002: President of the Medical Experts Committee (MEC) of the Swiss National Health Authorities (Swissmedic)
- January 2006: President of the succession committee for Prof. F. Bühler (pharmaceutical medicine at the University of Basel)
- 2006: Member of the election committee for a professorship in „Molecular and Systemic Toxicology“, Department of Pharmaceutical Sciences, University of Basel
- 2009: Member of the election committee for a professorship in „Clinical Pharmacy“, Department of Pharmaceutical Sciences, University of Basel
- 2009: Member of the election committee for a professorship in „Pharmaceutical Technology“, Department of Pharmaceutical Sciences, University of Basel
- 2010: Member of the election committee for a professorship in „Biopharmacy“, Department of Pharmaceutical Sciences, University of Basel
- 2010: President of the evaluation committee regarding the promotion of Prof. K. Vogt, Medical Faculty, University of Basel

Memberships in Academic and Professional Societies

- January 1994 - October 1998: Board member of the Working Group of the Swiss Association for the Study of the Liver (SASL)
- August 1996 – July 1999: Member of the Scientific Committee of the European Association for the Study of the Liver (EASL)
- May 1998 – April 2002: President of the Swiss Society of Clinical Pharmacology & Toxicology
- January 2001- December 2005: Member of the board of the Swiss Society of Pharmacology and Toxicology
- May 2002 – April 2005: Member of the board of the Swiss Society of Clinical Pharmacology & Toxicology

Publications

Articles in PubMed (mostly peer-reviewed)

1. Bachmann C, Krähenbühl S, Colombo JP, Schubiger G, Jaggi KH, Tönz O. N-acetylglutamate synthetase deficiency: a disorder of ammonia detoxication. *N Engl J Med* 1981;304:543.
2. Bachmann C, Krähenbühl S, Colombo JP. Purification and properties of acetyl-CoA:L-glutamate N-acetyltransferase from human liver. *Biochem J* 1982;205:123-127.
3. Colombo JP, Krähenbühl S, Bachmann C, Aeberhard P. N-Acetylglutamate synthetase: enzyme assay in human liver. *J Clin Chem Clin Biochem* 1982;20:325-329.
4. Reichen J, Krähenbühl S, Küpfer A, Sägesser H, Karlaganis G. Defective bile acid transport in an animal model of defective debrisoquine hydroxylation. *Biochem Pharmacol* 1986;35:753-759.
5. Krähenbühl S, Reichen J. Canalicular bile flow and bile salt secretion are maintained in rats with liver cirrhosis. Further evidence for the intact cell hypothesis. *J Hepatol* 1988;7:63-71.
6. Knuchel J, Krähenbühl S, Zimmermann A, Reichen J. Effect of secretin on bile formation in rats with cirrhosis of the liver: structure-function relationship. *Gastroenterology* 1989;97:950-957.
7. Krähenbühl S, Meier-Abt PJ, Reichen J. Taurocholate transport by liver plasma membrane vesicles is not altered in cirrhotic rats. *J Hepatol* 1989;9:1-9.
8. Krähenbühl S, Stucki J, Reichen J. Mitochondrial function in carbon tetrachloride-induced cirrhosis in the rat. Qualitative and quantitative defects. *Biochem Pharmacol* 1989;38:1583-1588.
9. Krahenbuhl S, Ray DB, Stabler SP, Allen RH, Brass EP. Increased hepatic mitochondrial capacity in rats with hydroxy-cobalamin[c-lactam]-induced methylmalonic aciduria. *J Clin Invest* 1990;86:2054-2061.
10. Krähenbühl S, Reichen J, Zimmermann A, Gehr P, Stucki J. Mitochondrial structure and function in CCl₄-induced cirrhosis in the rat. *Hepatology* 1990;12:526-532.
11. Krahenbuhl S, Brass EP. Inhibition of hepatic propionyl-CoA synthetase activity by organic acids. Reversal of propionate inhibition of pyruvate metabolism. *Biochem Pharmacol* 1991;41:1015-1023.
12. Krahenbuhl S, Brass EP. Fuel homeostasis and carnitine metabolism in rats with secondary biliary cirrhosis. *Hepatology* 1991;14:927-934.
13. Krahenbuhl S, Chang M, Brass EP, Hoppel CL. Decreased activities of ubiquinol:ferricytochrome c oxidoreductase (complex III) and ferrocycytochrome c: oxygen oxidoreductase (complex IV) in liver mitochondria from rats with hydroxycobalamin[c-lactam]-induced methylmalonic aciduria. *J Biol Chem* 1991;266:20998-21003.
14. Krahenbuhl S, Weber FL, Jr., Brass EP. Decreased hepatic glycogen content and accelerated response to starvation in rats with carbon tetrachloride-induced cirrhosis. *Hepatology* 1991;14:1189-1195.
15. Tandler B, Krahenbuhl S, Brass EP. Unusual mitochondria in the hepatocytes of rats treated with a vitamin B12 analogue. *Anat Rec* 1991;231:1-6.
16. Krähenbühl S, Krähenbühl-Glauser S, Stucki J, Gehr P, Reichen J. Stereological and functional analysis of liver mitochondria from rats with secondary biliary cirrhosis: impaired mitochondrial metabolism and increased mitochondrial content per hepatocyte. *Hepatology* 1992;15:1167-1172.
17. Krahenbuhl S, Minkler PE, Hoppel CL. Derivatization of isolated endogenous butyrobetaine with 4'-bromophenacyl trifluoromethanesulfonate followed by high-performance liquid chromatography. *J Chromatogr* 1992;573:3-10.
18. Krähenbühl S, Reichen J. Adaptation of mitochondrial metabolism in liver cirrhosis. Different strategies to maintain a vital function. *Scand J Gastroenterol Suppl* 1992;193:90-96.
19. Krähenbühl S, Stucki J, Reichen J. Reduced activity of the electron transport chain in liver mitochondria isolated from rats with secondary biliary cirrhosis. *Hepatology* 1992;15:1160-1166.
20. Hasler F, Krapf R, Brenneisen R, Bourquin D, Krähenbühl S. Determination of 18 beta-glycyrrhetic acid in biological fluids from humans and rats by solid-phase extraction and high-performance liquid chromatography. *J Chromatogr* 1993;620:73-82.
21. Herren T, Como F, Krähenbühl S, Wyss PA. [Therapy of acute salicylate poisoning]. *Schweiz Med Wochenschr* 1993;123:1775-1783.
22. Krähenbühl S. Alterations in mitochondrial function and morphology in chronic liver disease: pathogenesis and potential for therapeutic intervention. *Pharmacol Ther* 1993;60:1-38.
23. Krähenbühl S, Grass P, Surve A, Kutz K, Reichen J. Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease. *Eur J Clin Pharmacol* 1993;45:247-253.
24. Krähenbühl S, Raisin J, Herren T. [Malignant neuroleptic syndrome under metoclopramide and neuroleptics in anuria]. *Schweiz Med Wochenschr* 1993;123:1359-1362.
25. Krähenbühl S, Reichen J. Decreased hepatic glucose production in rats with carbon tetrachloride-induced cirrhosis. *J Hepatol* 1993;19:64-70.

26. Ambühl PM, Ballmer PE, Krähenbühl S. [Fulminant hepatitis: pathogenesis, clinical aspects and management]. *Schweiz Med Wochenschr* 1994;124:368-380.
27. Frenzer A, Gyr T, Schaer HM, Herren H, Krähenbühl S, Schaer M. [Triplet pregnancy with HELLP syndrome and transient diabetes insipidus]. *Schweiz Med Wochenschr* 1994;124:687-691.
28. Friolet R, Hoppeler H, Krähenbühl S. Relationship between the coenzyme A and the carnitine pools in human skeletal muscle at rest and after exhaustive exercise under normoxic and acutely hypoxic conditions. *J Clin Invest* 1994;94:1490-1495.
29. Krähenbühl S, Fischer S, Talos C, Reichen J. Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: dose-response study in isolated rat liver mitochondria. *Hepatology* 1994;20:1595-1601.
30. Krähenbühl S, Hasler F, Frey BM, Frey FJ, Brenneisen R, Krapf R. Kinetics and dynamics of orally administered 18 beta-glycyrrhetic acid in humans. *J Clin Endocrinol Metab* 1994;78:581-585.
31. Krähenbühl S, Hasler F, Krapf R. Analysis and pharmacokinetics of glycyrrhizic acid and glycyrrhetic acid in humans and experimental animals. *Steroids* 1994;59:121-126.
32. Krähenbühl S, Talos C, Fischer S, Reichen J. Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria. *Hepatology* 1994;19:471-479.
33. Krähenbühl S, Talos C, Reichen J. Mechanisms of impaired hepatic fatty acid metabolism in rats with long-term bile duct ligation. *Hepatology* 1994;19:1272-1281.
34. Krähenbühl S, Talos C, Wiesmann U, Hoppel CL. Development and evaluation of a spectrophotometric assay for complex III in isolated mitochondria, tissues and fibroblasts from rats and humans. *Clin Chim Acta* 1994;230:177-187.
35. Berardi S, Hagenbuch B, Carafoli E, Krähenbühl S. Characterization of the endogenous carnitine transport and expression of a rat renal Na(+)-dependent carnitine transport system in *Xenopus laevis* oocytes. *Biochem J* 1995;309 (Pt 2):389-393.
36. Frenzer A, Schubarth P, Soucek M, Krähenbühl S. Disappearance of a large mediastinal pseudocyst in a patient with chronic alcoholic pancreatitis after total parenteral nutrition. *Eur J Gastroenterol Hepatol* 1995;7:369-371.
37. Krähenbühl S. [Carnitine: vitamin or doping?]. *Ther Umsch* 1995;52:687-692.
38. Krähenbühl S, Mang G, Kupferschmidt H, Meier PJ, Krause M. Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity. *Gut* 1995;37:140-143.
39. Krähenbühl S, Marti U, Grant I, Garlick PJ, Ballmer PE. Characterization of mechanisms causing hypoalbuminemia in rats with long-term bile duct ligation. *J Hepatol* 1995;23:79-86.
40. Krähenbühl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ. Case report: reversible QT prolongation with torsades de pointes in a patient with pimozone intoxication. *Am J Med Sci* 1995;309:315-316.
41. Krähenbühl S, Talos C, Lauterburg BH, Reichen J. Reduced antioxidative capacity in liver mitochondria from bile duct ligated rats. *Hepatology* 1995;22:607-612.
42. Kupferschmidt H, Bont A, Schnorf H, Landis T, Walter E, Peter J, Krähenbühl S, et al. Transient cortical blindness and bioccipital brain lesions in two patients with acute intermittent porphyria. *Ann Intern Med* 1995;123:598-600.
43. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S. Interaction between grapefruit juice and midazolam in humans. *Clin Pharmacol Ther* 1995;58:20-28.
44. Meier C, Stey C, Brack T, Maggiorini M, Risti B, Krähenbühl S. [Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of the hepatic cytochrome P450 enzyme system activity]. *Schweiz Med Wochenschr* 1995;125:1342-1346.
45. Stieger B, O'Neill B, Krähenbühl S. Characterization of L-carnitine transport by rat kidney brush-border-membrane vesicles. *Biochem J* 1995;309 (Pt 2):643-647.
46. Colombani P, Wenk C, Kunz I, Krähenbühl S, Kuhnt M, Arnold M, Frey-Rindova P, et al. Effects of L-carnitine supplementation on physical performance and energy metabolism of endurance-trained athletes: a double-blind crossover field study. *Eur J Appl Physiol Occup Physiol* 1996;73:434-439.
47. Fattinger KE, Rentsch KM, Meier PJ, Dazzi H, Krähenbühl S. Safety of liver donation after fatal intoxication with the tricyclic antidepressant trimipramine. *Transplantation* 1996;62:1259-1262.
48. Green AL, Hultman E, Macdonald IA, Sewell DA, Greenhaff PL. Carbohydrate ingestion augments skeletal muscle creatine accumulation during creatine supplementation in humans. *Am J Physiol* 1996;271:E821-826.
49. Kind B, Fattinger K, Krähenbühl S, Meier-Abt PJ. [Clinicopharmacological case report (3). Drug-induced angioedema]. *Praxis (Bern 1994)* 1996;85:567-569.
50. Kind B, Fattinger K, Krähenbühl S, Meier-Abt PJ. [The clinicopharmacological case (5). serotonin reuptake inhibitor and 5-HT3-receptor antagonists: are there clinically relevant interactions?]. *Praxis (Bern 1994)* 1996;85:1490-1492.
51. Kind B, Krähenbühl S, Wyss PA, Meier-Abt PJ. [Clinical-toxicological case (1). Dosage of N-acetylcysteine in acute paracetamol poisoning]. *Praxis (Bern 1994)* 1996;85:935-938.

52. Krahenbuhl L, Talos C, Reichen J, Krähenbühl S. Progressive decrease in tissue glycogen content in rats with long-term cholestasis. *Hepatology* 1996;24:902-907.
53. Krähenbühl S. Carnitine metabolism in chronic liver disease. *Life Sci* 1996;59:1579-1599.
54. Krähenbühl S, Schäfer T, Wiesmann U. Determination of the activities of the enzyme complexes of the electron transport chain in human fibroblasts. *Clin Chim Acta* 1996;253:79-90.
55. Krähenbühl S, Smith-Gamble V, Hoppel CL. Pharmacokinetic interaction between diltiazem and nortriptyline. *Eur J Clin Pharmacol* 1996;49:417-419.
56. Kupferschmidt H, Langenegger T, Krähenbühl S. [Pericarditis in chronic inflammatory bowel disease: underlying disease or side effects of therapy? Clinical problem solving]. *Schweiz Med Wochenschr* 1996;126:2184-2190.
57. Meier C, Hess C, Meier-Abt PJ, Krähenbühl S. [A clinical-pharmacological case (1). Action of cisapride (Prepulsid) on bladder function]. *Praxis (Bern 1994)* 1996;85:62-64.
58. Ruesch S, Krähenbühl S, Kleinle S, Liechti-Gallati S, Schaffner T, Wermuth B, Weber J, et al. Combined 3-methylglutaconic and 3-hydroxy-3-methylglutaric aciduria with endocardial fibroelastosis and dilatative cardiomyopathy in male and female siblings with partial deficiency of complex II/III in fibroblasts. *Enzyme Protein* 1996;49:321-329.
59. Ambühl PM, Ballmer PE, Krähenbühl S, Krapf R. Quantification and predictors of plasma volume expansion from mannitol treatment. *Intensive Care Med* 1997;23:1159-1164.
60. Baerlocher KE, Steinmann B, Aguzzi A, Krähenbühl S, Roe CR, Vianey-Saban C. Short-chain acyl-CoA dehydrogenase deficiency in a 16-year-old girl with severe muscle wasting and scoliosis. *J Inher Metab Dis* 1997;20:427-431.
61. Fattinger K, Braunschweig S, Reichen J, Meier-Abt PJ, Krähenbühl S. [Liver injury under tuberculostatic treatment]. *Praxis (Bern 1994)* 1997;86:626-629.
62. Forestier M, Solioz M, Isbeki F, Talos C, Reichen J, Krähenbühl S. Hepatic mitochondrial proliferation in rats with secondary biliary cirrhosis: time course and mechanisms. *Hepatology* 1997;26:386-391.
63. Ha HR, Follath F, Bloemhard Y, Krähenbühl S. Determination of saquinavir in human plasma by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1997;694:427-433.
64. Kleinle S, Wiesmann U, Superti-Furga A, Krähenbühl S, Boltshauser E, Reichen J, Liechti-Gallati S. Detection and characterization of mitochondrial DNA rearrangements in Pearson and Kearns-Sayre syndromes by long PCR. *Hum Genet* 1997;100:643-650.
65. Krähenbühl L, Reichen J, Talos C, Krähenbühl S. Benzoic acid metabolism reflects hepatic mitochondrial function in rats with long-term extrahepatic cholestasis. *Hepatology* 1997;25:278-283.
66. Krähenbühl S. [Consequences of cholestasis from the hepatologist's viewpoint]. *Schweiz Med Wochenschr* 1997;127:821-828.
67. Krähenbühl S, Reichen J. Carnitine metabolism in patients with chronic liver disease. *Hepatology* 1997;25:148-153.
68. Laubscher B, Janzer RC, Krähenbühl S, Hirt L, Deonna T. Ragged-red fibers and complex I deficiency in a neonate with arthrogyriposis congenita. *Pediatr Neurol* 1997;17:249-251.
69. Mahler H, Pasi A, Kramer JM, Schulte P, Scoging AC, Bär W, Krähenbühl S. Fulminant liver failure in association with the emetic toxin of *Bacillus cereus*. *N Engl J Med* 1997;336:1142-1148.
70. Berardi S, Stieger B, Wachter S, O'Neill B, Krahenbühl S. Characterization of a sodium-dependent transport system for butyrobetaine into rat liver plasma membrane vesicles. *Hepatology* 1998;28:521-525.
71. Heuberger W, Berardi S, Jacky E, Pey P, Krähenbühl S. Increased urinary excretion of carnitine in patients treated with cisplatin. *Eur J Clin Pharmacol* 1998;54:503-508.
72. Imoberdorf R, Krähenbühl S, Krapf R. [Rhabdomyolysis in carnitine palmitoyltransferase II deficiency: developments in pathophysiology, diagnosis and therapy]. *Schweiz Med Wochenschr* 1998;128:1024-1029.
73. Kleinle S, Schneider V, Moosmann P, Brandner S, Krähenbühl S, Liechti-Gallati S. A novel mitochondrial tRNA(Phe) mutation inhibiting anticodon stem formation associated with a muscle disease. *Biochem Biophys Res Commun* 1998;247:112-115.
74. Krähenbühl L, Schäfer M, Krähenbühl S. Reversibility of hepatic mitochondrial damage in rats with long-term cholestasis. *J Hepatol* 1998;28:1000-1007.
75. Krähenbühl S. [Physiologic bases for the use of L-carnitine in cardiology]. *Praxis (Bern 1994)* 1998;87:102-107.
76. Krähenbühl S. [Adjusting dosage of drugs in patients with kidney or liver failure]. *Schweiz Med Wochenschr* 1998;128:189-194.
77. Krähenbühl S, Menafoglio A, Giostra E, Gallino A. Serious interaction between mibefradil and tacrolimus. *Transplantation* 1998;66:1113-1115.

78. Kronenberg A, Krähenbühl S, Zimmermann A, Streuli R. [Severe hepatocellular damage after administration of paracetamol and chlorzoxazone in therapeutic dosage]. *Praxis (Bern)* 1994;87:1356-1360.
79. Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, Krähenbühl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. *Br J Clin Pharmacol* 1998;45:355-359.
80. Krähenbühl L, Hagenbuch B, Berardi S, Schäfer M, Krähenbühl S. Rapid normalization of hepatic glycogen metabolism in rats with long-term bile duct ligation after biliodigestive anastomosis. *J Hepatol* 1999;31:656-663.
81. Krähenbühl S. Acarbose and acetaminophen--a dangerous combination? *Hepatology* 1999;29:285-287.
82. Krähenbühl S, Kleinle S, Henz S, Leibundgut K, Liechti S, Zimmermann A, Wiesmann U. Microvesicular steatosis, hemosiderosis and rapid development of liver cirrhosis in a patient with Pearson's syndrome. *J Hepatol* 1999;31:550-555.
83. Krähenbühl S, Willer B, Brühlmann P, Hoppeler H, Stucki G. Carnitine homeostasis in patients with rheumatoid arthritis. *Clin Chim Acta* 1999;279:35-45.
84. Wächter S, Krähenbühl L, Schäfer M, Krähenbühl S. The liver carnitine pool reflects alterations in hepatic fatty acid metabolism in rats with bile duct ligation before and after biliodigestive anastomosis. *J Hepatol* 1999;30:242-248.
85. Berardi S, Stieger B, Hagenbuch B, Carafoli E, Krähenbühl S. Characterization of L-carnitine transport into rat skeletal muscle plasma membrane vesicles. *Eur J Biochem* 2000;267:1985-1994.
86. Brooks H, Krähenbühl S. Development of a new assay for complex I of the respiratory chain. *Clin Chem* 2000;46:345-350.
87. Drewe J, Krähenbühl S. [Clinical pharmacology: proteins for the transport of drugs]. *Schweiz Med Wochenschr* 2000;130:727-731.
88. Hunger RE, Paredes BE, Quattropiani C, Krähenbühl S, Braathen LR. Primary cutaneous cryptococcosis in a patient with systemic immunosuppression after liver transplantation. *Dermatology* 2000;200:352-355.
89. Krähenbühl L, Ledermann M, Lang C, Krähenbühl S. Relationship between hepatic mitochondrial functions in vivo and in vitro in rats with carbon tetrachloride-induced liver cirrhosis. *J Hepatol* 2000;33:216-223.
90. Krähenbühl S, Brandner S, Kleinle S, Liechti S, Straumann D. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. *Liver* 2000;20:346-348.
91. Krähenbühl S, Brass EP, Hoppel CL. Decreased carnitine biosynthesis in rats with secondary biliary cirrhosis. *Hepatology* 2000;31:1217-1223.
92. Noce R, Paredes BE, Pichler WJ, Krähenbühl S. Acute generalized exanthematic pustulosis (AGEP) in a patient treated with furosemide. *Am J Med Sci* 2000;320:331-333.
93. Vernez L, Thormann W, Krähenbühl S. Analysis of carnitine and acylcarnitines in urine by capillary electrophoresis. *J Chromatogr A* 2000;895:309-316.
94. Willer B, Stucki G, Hoppeler H, Brühlmann P, Krähenbühl S. Effects of creatine supplementation on muscle weakness in patients with rheumatoid arthritis. *Rheumatology (Oxford)* 2000;39:293-298.
95. Brooks H, Krähenbühl S. Identification and tissue distribution of two differentially spliced variants of the rat carnitine transporter OCTN2. *FEBS Lett* 2001;508:175-180.
96. Krähenbühl S. Mitochondria: important target for drug toxicity? *J Hepatol* 2001;34:334-336.
97. Krähenbühl S. Alcohol-induced myopathy: what is the role of mitochondria? *Hepatology* 2001;34:210-211.
98. Lang C, Schäfer M, Serra D, Hegardt F, Krähenbühl L, Krähenbühl S. Impaired hepatic fatty acid oxidation in rats with short-term cholestasis: characterization and mechanism. *J Lipid Res* 2001;42:22-30.
99. Quattropiani C, Schneider M, Helbling A, Zimmermann A, Krähenbühl S. Cholangiopathy after short-term administration of piperacillin and imipenem/cilastatin. *Liver* 2001;21:213-216.
100. Russmann S, Zimmermann A, Krähenbühl S, Kern B, Reichen J. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. *Eur J Gastroenterol Hepatol* 2001;13:287-290.
101. Spaniol M, Bracher R, Ha HR, Follath F, Krähenbühl S. Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. *J Hepatol* 2001;35:628-636.
102. Spaniol M, Brooks H, Auer L, Zimmermann A, Solioz M, Stieger B, Krähenbühl S. Development and characterization of an animal model of carnitine deficiency. *Eur J Biochem* 2001;268:1876-1887.
103. Balmelli N, Dominé F, Pfisterer M, Krähenbühl S, Marsch S. Fatal drug interaction between cholestyramine and phenprocoumon. *Eur J Intern Med* 2002;13:210-211.
104. Lang C, Berardi S, Schäfer M, Serra D, Hegardt FG, Krähenbühl L, Krähenbühl S. Impaired ketogenesis is a major mechanism for disturbed hepatic fatty acid metabolism in rats with long-term cholestasis and after relief of biliary obstruction. *J Hepatol* 2002;37:564-571.

105. Lang C, Schäfer M, Varga L, Zimmermann A, Krähenbühl S, Krähenbühl L. Hepatic and skeletal muscle glycogen metabolism in rats with short-term cholestasis. *J Hepatol* 2002;36:22-29.
106. Meier CR, Krähenbühl S, Schlienger RG, Jick H. Association between body mass index and liver disorders: an epidemiological study. *J Hepatol* 2002;37:741-747.
107. Mordasini MR, Krähenbühl S, Schlienger RG. Appropriateness of digoxin level monitoring. *Swiss Med Wkly* 2002;132:506-512.
108. Schlienger RG, Keller MJ, Krähenbühl S. Tolterodine-associated acute mixed liver injury. *Ann Pharmacother* 2002;36:817-819.
109. Wächter S, Vogt M, Kreis R, Boesch C, Bigler P, Hoppeler H, Krähenbühl S. Long-term administration of L-carnitine to humans: effect on skeletal muscle carnitine content and physical performance. *Clin Chim Acta* 2002;318:51-61.
110. Affolter N, Krähenbühl S, Schlienger RG. Appropriateness of serum level determinations of antiepileptic drugs. *Swiss Med Wkly* 2003;133:591-597.
111. Krähenbühl L, Lang C, Lüdes S, Seiler C, Schäfer M, Zimmermann A, Krähenbühl S. Reduced hepatic glycogen stores in patients with liver cirrhosis. *Liver Int* 2003;23:101-109.
112. Krähenbühl S. [Abuse of benzodiazepines and similar substances]. *Ther Umsch* 2003;60:335-340.
113. Krähenbühl S, Drewe J. [Not Available]. *Ther Umsch* 2003;60:307.
114. Spaniol M, Kaufmann P, Beier K, Wüthrich J, Török M, Scharnagl H, März W, et al. Mechanisms of liver steatosis in rats with systemic carnitine deficiency due to treatment with trimethylhydraziniumpropionate. *J Lipid Res* 2003;44:144-153.
115. Tietz A, Heim MH, Eriksson U, Marsch S, Terracciano L, Krähenbühl S. Fulminant liver failure associated with clarithromycin. *Ann Pharmacother* 2003;37:57-60.
116. Todesco L, Török M, Krähenbühl S, Wenk M. Determination of -3858G-->A and -164C-->A genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the -3858G-->A mutation between Caucasians and Asians. *Eur J Clin Pharmacol* 2003;59:343-346.
117. Vernez L, Hopfgartner G, Wenk M, Krähenbühl S. Determination of carnitine and acylcarnitines in urine by high-performance liquid chromatography-electrospray ionization ion trap tandem mass spectrometry. *J Chromatogr A* 2003;984:203-213.
118. Vrtic F, Haefeli WE, Drewe J, Krähenbühl S, Wenk M. Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug. *Br J Clin Pharmacol* 2003;55:191-198.
119. Zaugg CE, Spaniol M, Kaufmann P, Bellahcene M, Barbosa V, Tolnay M, Buser PT, et al. Myocardial function and energy metabolism in carnitine-deficient rats. *Cell Mol Life Sci* 2003;60:767-775.
120. Giostra E, Kullak-Ublick GA, Keller W, Fried R, Vanlemmens C, Kraehenbuhl S, Locher S, et al. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. *Transpl Int* 2004;17:169-176.
121. Krähenbühl S. [Toxic liver injuries]. *Ther Umsch* 2004;61:529-534.
122. Krähenbühl S. [Pharmacokinetics and pharmacodynamics in the elderly]. *Praxis (Bern 1994)* 2004;93:1305-1310.
123. Rätz Bravo AE, Egger SS, Crespo S, Probst WL, Krähenbühl S. Lithium intoxication as a result of an interaction with rofecoxib. *Ann Pharmacother* 2004;38:1189-1193.
124. Roten L, Schoenenberger RA, Krähenbühl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. *Ann Pharmacother* 2004;38:978-981.
125. Schnyder A, Krähenbühl S, Török M, Drewe J, Huwyler J. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes. *Biochem J* 2004;377:61-67.
126. Vernez L, Wenk M, Krähenbühl S. Determination of carnitine and acylcarnitines in plasma by high-performance liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2004;18:1233-1238.
127. Wenk M, Todesco L, Krähenbühl S. Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. *Br J Clin Pharmacol* 2004;57:495-499.
128. Blanco I, Krähenbühl S, Schlienger RG. Corticosteroid-associated tendinopathies: an analysis of the published literature and spontaneous pharmacovigilance data. *Drug Saf* 2005;28:633-643.
129. Delcò F, Tchambaz L, Schlienger R, Drewe J, Krähenbühl S. Dose adjustment in patients with liver disease. *Drug Saf* 2005;28:529-545.
130. Egger SS, Krähenbühl S, Schlienger RG. [Dealing with adverse drug reactions in dentistry. Procedures on encountering adverse drug reactions and goal of the Swiss Pharmacovigilance system]. *Schweiz Monatsschr Zahnmed* 2005;115:1209-1218.

131. Egger SS, Sawatzki MG, Drewe J, Krähenbühl S. Life-threatening hemorrhage after dalteparin therapy in a patient with impaired renal function. *Pharmacotherapy* 2005;25:881-885.
132. Kaufmann P, Török M, Hänni A, Roberts P, Gasser R, Krähenbühl S. Mechanisms of benzarone and benzobromarone-induced hepatic toxicity. *Hepatology* 2005;41:925-935.
133. Krähenbühl-Melcher A, Krähenbühl S. [Hospital drug safety: medication errors and adverse drug reactions]. *Praxis (Bern 1994)* 2005;94:1031-1038.
134. Rätz Bravo AE, Drewe J, Schlienger RG, Krähenbühl S, Pargger H, Ummenhofer W. Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature. *Crit Care Med* 2005;33:128-134; discussion 245-126.
135. Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, Hess L, Schlienger RG, Krähenbühl S. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. *Drug Saf* 2005;28:263-275.
136. Richter B, Inderbitzin D, Lang C, Krähenbühl S, Krähenbühl L. Hepatic carbohydrate metabolism in rats after laparotomy and laparoscopy. *Surg Endosc* 2005;19:1475-1482.
137. Schnyder A, Krähenbühl S, Drewe J, Huwyler J. Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects. *J Drug Target* 2005;13:325-335.
138. Becker C, Hvalic C, Delmore G, Krähenbühl S, Schlienger R. [Recurrent acute pancreatitis during pravastatin-therapy]. *Praxis (Bern 1994)* 2006;95:111-116.
139. Beltinger J, Haschke M, Kaufmann P, Michot M, Terracciano L, Krähenbühl S. Hepatic veno-occlusive disease associated with immunosuppressive cyclophosphamide dosing and roxithromycin. *Ann Pharmacother* 2006;40:767-770.
140. Bodmer M, Egger SS, Hohenstein E, Beltraminelli H, Krähenbühl S. Lichenoid eruption associated with the use of nebivolol. *Ann Pharmacother* 2006;40:1688-1690.
141. Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krähenbühl S. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase. *Digestion* 2006;74:28-32.
142. Egger SS, Bachmann A, Hubmann N, Schlienger RG, Krähenbühl S. Prevalence of potentially inappropriate medication use in elderly patients: comparison between general medical and geriatric wards. *Drugs Aging* 2006;23:823-837.
143. Egger SS, Studer IG, Rätz Bravo AE, Krähenbühl S. [Minocycline-induced lupus erythematoses]. *Praxis (Bern 1994)* 2006;95:1297-1303.
144. Grunder G, Zysset-Aschmann Y, Vollenweider F, Maier T, Krähenbühl S, Drewe J. Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers. *Antimicrob Agents Chemother* 2006;50:68-72.
145. Kaufmann P, Haschke M, Török M, Beltinger J, Bogman K, Wenk M, Terracciano L, et al. Mechanisms of venoocclusive disease resulting from the combination of cyclophosphamide and roxithromycin. *Ther Drug Monit* 2006;28:766-774.
146. Kaufmann P, Török M, Zahno A, Waldhauser KM, Brecht K, Krähenbühl S. Toxicity of statins on rat skeletal muscle mitochondria. *Cell Mol Life Sci* 2006;63:2415-2425.
147. Kummer O, Haschke M, Tuchscherer D, Lampert M, Martius F, Krähenbühl S. [Agranulocytosis in a patient treated with metamizole and clopidogrel]. *Praxis (Bern 1994)* 2006;95:1743-1745; quiz 1746-1747.
148. Porta F, Takala J, Weikert C, Kaufmann P, Krähenbühl S, Jakob SM. Effect of endotoxin, dobutamine and dopamine on muscle mitochondrial respiration in vitro. *J Endotoxin Res* 2006;12:358-366.
149. Ramelli GP, Gallati S, Weis J, Krähenbühl S, Burgunder JM. Point mutation tRNA(Ser(UCN)) in a child with hearing loss and myoclonus epilepsy. *J Child Neurol* 2006;21:253-255.
150. Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, Hess L, Schlienger RG, Krähenbühl S. [Prevalence of potential drug-drug interactions in ambulatory patients with statin therapy]. *Praxis (Bern 1994)* 2006;95:139-146.
151. Sidharta PN, Wagner FD, Bohnemeier H, Jungnik A, Halabi A, Krähenbühl S, Chadha-Boreham H, et al. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. *Clin Pharmacol Ther* 2006;80:246-256.
152. Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, Krähenbühl S, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. *Am Heart J* 2006;152:27-38.
153. Straubhaar B, Krähenbühl S, Schlienger RG. The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge. *Drug Saf* 2006;29:79-90.
154. Tchambaz L, Schlatter C, Jakob M, Krähenbühl A, Wolf P, Krähenbühl S. Dose adaptation of antineoplastic drugs in patients with liver disease. *Drug Saf* 2006;29:509-522.

155. Vernez L, Dickenmann M, Steiger J, Wenk M, Krähenbühl S. Effect of L-carnitine on the kinetics of carnitine, acylcarnitines and butyrobetaine in long-term haemodialysis. *Nephrol Dial Transplant* 2006;21:450-458.
156. Waldhauser KM, Török M, Ha HR, Thomet U, Konrad D, Brecht K, Follath F, et al. Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. *J Pharmacol Exp Ther* 2006;319:1413-1423.
157. Wenk M, Droll A, Krähenbühl S. Fast and reliable determination of the antifungal drug voriconazole in plasma using monolithic silica rod liquid chromatography. *J Chromatogr B Analyt Technol Biomed Life Sci* 2006;832:313-316.
158. Wenk M, Haegeli L, Brunner H, Krähenbühl S. Determination of furosemide in plasma and urine using monolithic silica rod liquid chromatography. *J Pharm Biomed Anal* 2006;41:1367-1370.
159. Belin GK, Krähenbühl S, Hauser PC. Direct determination of valproic acid in biological fluids by capillary electrophoresis with contactless conductivity detection. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007;847:205-209.
160. Bodmer M, Amico P, Mihatsch MJ, Haschke M, Kummer O, Krähenbühl S, Mayr M. Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. *Nephrol Dial Transplant* 2007;22:2366-2370.
161. Egger SS, Rätz Bravo AE, Hess L, Schlienger RG, Krähenbühl S. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. *Drugs Aging* 2007;24:429-440.
162. Giger U, Büchler M, Farhadi J, Berger D, Hüsler J, Schneider H, Krähenbühl S, et al. Preoperative immunonutrition suppresses perioperative inflammatory response in patients with major abdominal surgery—a randomized controlled pilot study. *Ann Surg Oncol* 2007;14:2798-2806.
163. Haegeli L, Brunner-La Rocca HP, Wenk M, Pfisterer M, Drewe J, Krähenbühl S. Sublingual administration of furosemide: new application of an old drug. *Br J Clin Pharmacol* 2007;64:804-809.
164. Indermitte J, Burkolter S, Drewe J, Krähenbühl S, Hersberger KE. Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients. *Drug Saf* 2007;30:71-80.
165. Krähenbühl S, Brauchli Y, Kummer O, Bodmer M, Trendelenburg M, Drewe J, Haschke M. Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage. *Digestion* 2007;75:232-237.
166. Krähenbühl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krähenbühl S. Drug-related problems in hospitals: a review of the recent literature. *Drug Saf* 2007;30:379-407.
167. Kummer O, Mossdorf E, Battegay M, Elzi L, Bodmer M, Krähenbühl S, Haschke M. Treatment of an atazanavir associated grade 4 hyperbilirubinaemia with efavirenz. *Gut* 2007;56:1477-1478.
168. Kummer O, Novakova K, Burkard T, Hammann F, Krähenbühl S, Bodmer M. [Drug-induced microscopic colitis]. *Praxis (Bern 1994)* 2007;96:1293-1297.
169. Link B, Haschke M, Wenk M, Krähenbühl S. Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2007;21:1531-1540.
170. Lüde S, Török M, Dieterle S, Knapp AC, Kaeufeler R, Jäggi R, Spornitz U, et al. Hepatic effects of *Cimicifuga racemosa* extract in vivo and in vitro. *Cell Mol Life Sci* 2007;64:2848-2857.
171. Vonbach P, Dubied A, Beer JH, Krähenbühl S. Recognition and management of potential drug-drug interactions in patients on internal medicine wards. *Eur J Clin Pharmacol* 2007;63:1075-1083.
172. Vonbach P, Reich R, Möll F, Krähenbühl S, Ballmer PE, Meier CR. Risk factors for gastrointestinal bleeding: a hospital-based case-control study. *Swiss Med Wkly* 2007;137:705-710.
173. Aschmann YZ, Kummer O, Linka A, Wenk M, Azzola A, Bodmer M, Krähenbühl S, et al. Pharmacokinetics and pharmacodynamics of sildenafil in a patient treated with human immunodeficiency virus protease inhibitors. *Ther Drug Monit* 2008;30:130-134.
174. Bodmer M, Burkard T, Kummer O, Beyrau R, Krähenbühl S, Haschke M. Pharmacokinetics and pharmacodynamics of quetiapine in a patient with a massive overdose. *Ther Drug Monit* 2008;30:553-556.
175. Bodmer M, Link B, Grignaschi N, Kummer O, Ruegg S, Haschke M, Krähenbühl S. Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. *Ther Drug Monit* 2008;30:120-124.
176. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Metformin, sulfonyleureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. *Diabetes Care* 2008;31:2086-2091.
177. Botomino A, Bruppacher R, Krähenbühl S, Hersberger KE. Change of body weight and lifestyle of persons at risk for diabetes after screening and counselling in pharmacies. *Pharm World Sci* 2008;30:222-226.
178. Brauchli YB, Gittermann M, Michot M, Krähenbühl S, Gnehm HE. A fatal tick bite occurring during the course of tick-borne encephalitis vaccination. *Pediatr Infect Dis J* 2008;27:363-365.

179. Brauchli YB, Scholer A, Schwietert M, Krähenbühl S. Undetectable phenytoin serum levels by an automated particle-enhanced turbidimetric inhibition immunoassay in a patient with monoclonal IgM lambda. *Clin Chim Acta* 2008;389:174-176.
180. Huwylar J, Drewe J, Krähenbühl S. Tumor targeting using liposomal antineoplastic drugs. *Int J Nanomedicine* 2008;3:21-29.
181. Knapp AC, Todesco L, Beier K, Terracciano L, Sägesser H, Reichen J, Krähenbühl S. Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores. *J Pharmacol Exp Ther* 2008;324:568-575.
182. Knapp AC, Todesco L, Torok M, Beier K, Krähenbühl S. Effect of carnitine deprivation on carnitine homeostasis and energy metabolism in mice with systemic carnitine deficiency. *Ann Nutr Metab* 2008;52:136-144.
183. Kummer O, Hammann F, Bodmer M, Novakova K, Krähenbühl S, Haschke M. [Drug-induced toxic hepatitis]. *Praxis (Bern 1994)* 2008;97:235-239; quiz 240-231.
184. Lampert ML, Kraehenbuehl S, Hug BL. Drug-related problems: evaluation of a classification system in the daily practice of a Swiss University Hospital. *Pharm World Sci* 2008;30:768-776.
185. Link B, Haschke M, Grignaschi N, Bodmer M, Aschmann YZ, Wenk M, Krähenbühl S. Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. *Br J Clin Pharmacol* 2008;66:473-484.
186. Lüde S, Török M, Dieterle S, Jäggi R, Büter KB, Krähenbühl S. Hepatocellular toxicity of kava leaf and root extracts. *Phytomedicine* 2008;15:120-131.
187. Poller B, Gutmann H, Krähenbühl S, Weksler B, Romero I, Couraud PO, Tuffin G, et al. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. *J Neurochem* 2008;107:1358-1368.
188. Todesco L, Bur D, Brooks H, Török M, Landmann L, Stieger B, Krähenbühl S. Pharmacological manipulation of L-carnitine transport into L6 cells with stable overexpression of human OCTN2. *Cell Mol Life Sci* 2008;65:1596-1608.
189. Vonbach P, Dubied A, Krähenbühl S, Beer JH. Evaluation of frequently used drug interaction screening programs. *Pharm World Sci* 2008;30:367-374.
190. Vonbach P, Dubied A, Krähenbühl S, Beer JH. Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. *Eur J Intern Med* 2008;19:413-420.
191. Waldhauser KM, Brecht K, Hebeisen S, Ha HR, Konrad D, Bur D, Krähenbühl S. Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues. *Br J Pharmacol* 2008;155:585-595.
192. Bodmer M, Brauchli YB, Krähenbühl S, Jick SS, Meier CR. Statin use and risk of gallstone disease followed by cholecystectomy. *Jama* 2009;302:2001-2007.
193. Giger U, Wente MN, Büchler MW, Krähenbühl S, Lerut J, Krähenbühl L. Endoscopic retroperitoneal neurectomy for chronic pain after groin surgery. *Br J Surg* 2009;96:1076-1081.
194. Kummer O, Haschke M, Hammann F, Bodmer M, Bruderer S, Regnault Y, Dingemans J, et al. Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. *Eur J Pharm Sci* 2009;38:384-388.
195. Pormsila W, Krähenbühl S, Hauser PC. Capillary electrophoresis with contactless conductivity detection for uric acid determination in biological fluids. *Anal Chim Acta* 2009;636:224-228.
196. Rätz Bravo AE, Hofer S, Krähenbühl S, Ludwig C. Fatal drug-drug interaction of brivudine and capecitabine. *Acta Oncol* 2009;48:631-633.
197. Schlatter C, Egger SS, Tchambaz L, Krähenbühl S. Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation. *Drug Saf* 2009;32:561-578.
198. Sidharta PN, Rave K, Heinemann L, Chiossi E, Krähenbühl S, Dingemans J. Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus. *Br J Clin Pharmacol* 2009;68:502-510.
199. Todesco L, Bodmer M, Vonwil K, Häussinger D, Krähenbühl S. Interaction between pivaloylcarnitine and L-carnitine transport into L6 cells overexpressing hOCTN2. *Chem Biol Interact* 2009;180:472-477.
200. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. *Diabetes Care* 2010;33:1304-1308.
201. Brauchli YB, Wais T, Gratwohl A, Heim D, Schipf A, Diebold J, Krähenbühl S. Fatal myocardial infarction during nilotinib treatment in a 60-year-old male patient. *Acta Oncol* 2010;49:523-525.
202. Daudel F, Tüller D, Krähenbühl S, Jakob SM, Takala J. Pulse pressure variation and volume responsiveness during acutely increased pulmonary artery pressure: an experimental study. *Crit Care* 2010;14:R122.
203. Egger SS, Meier S, Leu C, Christen S, Gratwohl A, Krähenbühl S, Haschke M. Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT. *Bone Marrow Transplant* 2010;45:1197-1203.

204. Grisouard J, Timper K, Radimerski TM, Frey DM, Peterli R, Kola B, Korbonits M, et al. Mechanisms of metformin action on glucose transport and metabolism in human adipocytes. *Biochem Pharmacol* 2010;80:1736-1745.
205. Haschke M, Suter K, Hofmann S, Witschi R, Fröhlich J, Imanidis G, Drewe J, et al. Pharmacokinetics and pharmacodynamics of nasally delivered midazolam. *Br J Clin Pharmacol* 2010;69:607-616.
206. Haschke M, Vitins T, Lüde S, Todesco L, Novakova K, Herrmann R, Krähenbühl S. Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs. *Nephrol Dial Transplant* 2010;25:426-433.
207. Joerger M, Huitema AD, Krähenbühl S, Schellens JH, Cerny T, Reni M, Zucca E, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. *Br J Cancer* 2010;102:673-677.
208. Krämer I, Rauber-Lüthy C, Kupferschmidt H, Krähenbühl S, Ceschi A. Minimal dose for severe poisoning and influencing factors in acute human clozapine intoxication: a 13-year retrospective study. *Clin Neuropharmacol* 2010;33:230-234.
209. Mullen PJ, Lüscher B, Scharnagl H, Krähenbühl S, Brecht K. Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. *Biochem Pharmacol* 2010;79:1200-1209.
210. Poller B, Drewe J, Krähenbühl S, Huwyler J, Gutmann H. Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. *Cell Mol Neurobiol* 2010;30:63-70.
211. Popov Y, Sverdlov DY, Bhaskar KR, Sharma AK, Millonig G, Patsenker E, Krahenbuhl S, et al. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. *Am J Physiol Gastrointest Liver Physiol* 2010;298:G323-334.
212. Pormsila W, Krähenbühl S, Hauser PC. Determination of carnitine in food and food supplements by capillary electrophoresis with contactless conductivity detection. *Electrophoresis* 2010;31:2186-2191.
213. Sawatzki M, Kummer O, Krähenbühl S, Siegemund M. [Seizure and non-cardiogenic pulmonary edema after intoxication]. *Internist (Berl)* 2010;51:528-532.
214. Schürch R, Todesco L, Novakova K, Mevissen M, Stieger B, Krähenbühl S. The plasma carnitine concentration regulates renal OCTN2 expression and carnitine transport in rats. *Eur J Pharmacol* 2010;635:171-176.
215. Taegtmeier AB, Zettler C, Siegemund M, Tsakiris DA, Rätz Bravo AE, Pargger H, Kraehenbuehl S, et al. Iloprost-induced thrombocytopenia: a case proven by rechallenge. *Eur Respir J* 2010;36:967-969.
216. Zahno A, Brecht K, Bodmer M, Bur D, Tsakiris DA, Krähenbühl S. Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro. *Br J Pharmacol* 2010;161:393-404.
217. Bruggisser M, Rätz Bravo AE, Krähenbühl S. [Severe pancytopenia and stomatitis in a patient treated with low-dose methotrexate]. *Praxis (Bern 1994)* 2011;100:765-774; quiz 772.
218. Derungs A, Schietzel S, Meyer MR, Maurer HH, Krähenbühl S, Liechti ME. Sympathomimetic toxicity in a case of analytically confirmed recreational use of naphyrone (naphthylpyrovalerone). *Clin Toxicol (Phila)* 2011;49:691-693.
219. Franz CC, Bruggisser M, Krähenbühl S, Rätz Bravo AE. [Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole]. *Praxis (Bern 1994)* 2011;100:273-284.
220. Giger U, Ouaisi M, Schmitz SF, Krähenbühl S, Krähenbühl L. Bile duct injury and use of cholangiography during laparoscopic cholecystectomy. *Br J Surg* 2011;98:391-396.
221. Halter J, Schüpbach W, Casali C, Elhasid R, Fay K, Hammans S, Illa I, et al. Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. *Bone Marrow Transplant* 2011;46:330-337.
222. Hoch M, Hoever P, Haschke M, Krähenbühl S, Dingemans J. Food effect and biocomparison of two formulations of the dual orexin receptor antagonist almorexant in healthy male subjects. *J Clin Pharmacol* 2011;51:1116-1121.
223. Kummer O, Hammann F, Moser C, Schaller O, Drewe J, Krähenbühl S. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. *Eur J Clin Pharmacol* 2011;67:63-71.
224. Mullen PJ, Zahno A, Lindinger P, Maseneni S, Felser A, Krähenbühl S, Brecht K. Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. *Biochim Biophys Acta* 2011;1813:2079-2087.

225. Pormsila W, Morand R, Krähenbühl S, Hauser PC. Capillary electrophoresis with contactless conductivity detection for the determination of carnitine and acylcarnitines in clinical samples. *J Chromatogr B Analyt Technol Biomed Life Sci* 2011;879:921-926.
226. Pormsila W, Morand R, Krähenbühl S, Hauser PC. Quantification of plasma lactate concentrations using capillary electrophoresis with contactless conductivity detection. *Electrophoresis* 2011;32:884-889.
227. Zahno A, Brecht K, Morand R, Maseneni S, Török M, Lindinger PW, Krähenbühl S. The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. *Biochem Pharmacol* 2011;81:432-441.
228. Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir. *Swiss Med Wkly* 2012;142:w13516.
229. Detampel P, Beck M, Krähenbühl S, Huwyler J. Drug interaction potential of resveratrol. *Drug Metab Rev* 2012;44:253-265.
230. Franz CC, Egger S, Born C, Rätz Bravo AE, Krähenbühl S. Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. *Eur J Clin Pharmacol* 2012;68:179-188.
231. Hardmeier M, Zimmermann R, Rüegg S, Pflüger M, Deuster S, Suter K, Donzelli M, et al. Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers. *Clin Pharmacol Ther* 2012;91:856-862.
232. Henkel V, Casaulta F, Seemüller F, Krähenbühl S, Obermeier M, Hüsler J, Möller HJ. Study design features affecting outcome in antidepressant trials. *J Affect Disord* 2012;141:160-167.
233. Hysek CM, Simmler LD, Nicola VG, Vischer N, Donzelli M, Krähenbühl S, Grouzmann E, et al. Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. *PLoS One* 2012;7:e36476.
234. Joerger M, Ferreri AJ, Krähenbühl S, Schellens JH, Cerny T, Zucca E, Huitema AD. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. *Br J Clin Pharmacol* 2012;73:240-247.
235. Maseneni S, Donzelli M, Taegtmeier AB, Brecht K, Krähenbühl S. Toxicity of clopidogrel and ticlopidine on human myeloid progenitor cells: importance of metabolites. *Toxicology* 2012;299:139-145.
236. Morand R, Todesco L, Donzelli M, Fischer-Barnicol D, Mullen PJ, Krähenbühl S. Effect of short- and long-term treatment with valproate on carnitine homeostasis in humans. *Ther Drug Monit* 2012;34:406-414.
237. Nezic L, Krähenbühl S, Rätz Bravo AE. [Diclofenac induced liver injuries]. *Praxis (Bern 1994)* 2012;101:371-379.
238. Pham TT, See HH, Morand R, Krähenbühl S, Hauser PC. Determination of free and total valproic acid in human plasma by capillary electrophoresis with contactless conductivity detection. *J Chromatogr B Analyt Technol Biomed Life Sci* 2012;907:74-78.
239. See HH, Schmidt-Marzinkowski J, Pormsila W, Morand R, Krähenbühl S, Hauser PC. Determination of creatine and phosphocreatine in muscle biopsy samples by capillary electrophoresis with contactless conductivity detection. *Anal Chim Acta* 2012;727:78-82.
240. Caduff Good A, Nobel D, Krähenbühl S, Geisen C, Henz S. Randomised trial of a clinical dosing algorithm to start anticoagulation with phenprocoumon. *Swiss Med Wkly* 2013;143:w13709.
241. Ceschi A, Rauber-Lüthy C, Kupferschmidt H, Banner NR, Ansari M, Krähenbühl S, Taegtmeier AB. Acute calcineurin inhibitor overdose: analysis of cases reported to a national poison center between 1995 and 2011. *Am J Transplant* 2013;13:786-795.
242. Felser A, Blum K, Lindinger PW, Bouitbir J, Krähenbühl S. Mechanisms of hepatocellular toxicity associated with dronedarone--a comparison to amiodarone. *Toxicol Sci* 2013;131:480-490.
243. Franz CC, Hildbrand C, Born C, Egger S, Rätz Bravo AE, Krähenbühl S. Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations. *Eur J Clin Pharmacol* 2013;69:1565-1573.
244. Giger-Pabst U, Lange J, Maurer C, Bucher C, Schreiber V, Schlumpf R, Kocher T, et al. Short-term preoperative supplementation of an immunoenriched diet does not improve clinical outcome in well-nourished patients undergoing abdominal cancer surgery. *Nutrition* 2013;29:724-729.
245. Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, Penninger J, et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. *Clin Pharmacokinet* 2013;52:783-792.
246. Hirzel E, Lindinger PW, Maseneni S, Giese M, Rhein VV, Eckert A, Hoch M, et al. Differential modulation of ROS signals and other mitochondrial parameters by the antioxidants MitoQ, resveratrol and curcumin in human adipocytes. *J Recept Signal Transduct Res* 2013;33:304-312.
247. Krähenbühl S. [Not Available]. *Ther Umsch* 2013;70:284-288.
248. Maseneni S, Donzelli M, Brecht K, Krähenbühl S. Toxicity of thienopyridines on human neutrophil granulocytes and lymphocytes. *Toxicology* 2013;308:11-19.

249. Morand R, Donzelli M, Haschke M, Krähenbühl S. Quantification of plasma carnitine and acylcarnitines by high-performance liquid chromatography-tandem mass spectrometry using online solid-phase extraction. *Anal Bioanal Chem* 2013;405:8829-8836.
250. Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl S, Froehlich TK, et al. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. *Cancer Chemother Pharmacol* 2013;71:361-370.
251. Nickel CH, Ruedinger JM, Messmer AS, Maile S, Peng A, Bodmer M, Kressig RW, et al. Drug-related emergency department visits by elderly patients presenting with non-specific complaints. *Scand J Trauma Resusc Emerg Med* 2013;21:15.
252. Wuillemin N, Adam J, Fontana S, Krähenbühl S, Pichler WJ, Yerly D. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin. *J Immunol* 2013;190:4956-4964.
253. Zahno A, Bouitbir J, Maseneni S, Lindinger PW, Brecht K, Krähenbühl S. Hepatocellular toxicity of clopidogrel: mechanisms and risk factors. *Free Radic Biol Med* 2013;65:208-216.
254. Ceschi A, Gregoriano C, Rauber-Lüthy C, Kupferschmidt H, Banner NR, Krähenbühl S, Taegtmeyer AB. Acute mycophenolate overdose: case series and systematic literature analysis. *Expert Opin Drug Saf* 2014;13:525-534.
255. Detampel P, Witzigmann D, Krähenbühl S, Huwyler J. Hepatocyte targeting using pegylated asialofetuin-conjugated liposomes. *J Drug Target* 2014;22:232-241.
256. Donzelli M, Derungs A, Serratore MG, Noppen C, Nezc L, Krähenbühl S, Haschke M. The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. *Clin Pharmacokinet* 2014;53:271-282.
257. Felser A, Lindinger PW, Schnell D, Kratschmar DV, Odermatt A, Mies S, Jenö P, et al. Hepatocellular toxicity of benzbromarone: effects on mitochondrial function and structure. *Toxicology* 2014;324:136-146.
258. Felser A, Stoller A, Morand R, Schnell D, Donzelli M, Terracciano L, Bouitbir J, et al. Hepatic toxicity of dronedarone in mice: role of mitochondrial β -oxidation. *Toxicology* 2014;323:1-9.
259. Gregoriano C, Ceschi A, Rauber-Lüthy C, Kupferschmidt H, Banner NR, Krähenbühl S, Taegtmeyer AB. Acute thiopurine overdose: analysis of reports to a National Poison Centre 1995-2013. *PLoS One* 2014;9:e86390.
260. Liakoni E, Rätz Bravo AE, Terracciano L, Heim M, Krähenbühl S. Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. *JAMA Intern Med* 2014;174:1683-1686.
261. Morand R, Bouitbir J, Felser A, Hench J, Handschin C, Frank S, Krähenbühl S. Effect of carnitine, acetyl-, and propionylcarnitine supplementation on the body carnitine pool, skeletal muscle composition, and physical performance in mice. *Eur J Nutr* 2014;53:1313-1325.
262. Nezc L, Derungs A, Bruggisser M, Tschudin-Sutter S, Krähenbühl S, Haschke M. Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy. *Eur J Clin Pharmacol* 2014;70:829-837.
263. Siller-Matula JM, Trenk D, Krähenbühl S, Michelson AD, Delle-Karth G. Clinical implications of drug-drug interactions with P2Y₁₂ receptor inhibitors. *J Thromb Haemost* 2014;12:2-13.
264. Taegtmeyer AB, Haschke M, Tchambaz L, Buylaert M, Tschöpl M, Beuers U, Drewe J, et al. A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls. *PLoS One* 2014;9:e97885.
265. Wuillemin N, Terracciano L, Beltraminelli H, Schlapbach C, Fontana S, Krähenbühl S, Pichler WJ, et al. T cells infiltrate the liver and kill hepatocytes in HLA-B(*):57:01-associated floxacillin-induced liver injury. *Am J Pathol* 2014;184:1677-1682.
266. Blaser LS, Tramonti A, Egger P, Haschke M, Krähenbühl S, Rätz Bravo AE. Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports. *Eur J Clin Pharmacol* 2015;71:209-217.
267. Bonifacio A, Sanvee GM, Bouitbir J, Krähenbühl S. The AKT/mTOR signaling pathway plays a key role in statin-induced myotoxicity. *Biochim Biophys Acta* 2015;1853:1841-1849.
268. Ceschi A, Heistermann E, Gros S, Reichert C, Kupferschmidt H, Banner NR, Krähenbühl S, et al. Acute sirolimus overdose: a multicenter case series. *PLoS One* 2015;10:e0128033.
269. Haegler P, Grünig D, Berger B, Krähenbühl S, Bouitbir J. Impaired mitochondrial function in HepG2 cells treated with hydroxy-cobalamin[c-lactam]: A cell model for idiosyncratic toxicity. *Toxicology* 2015;336:48-58.
270. Krähenbühl S. [Adverse drug reaction - Definitions, risk factors and pharmacovigilance]. *Ther Umsch* 2015;72:669-671.
271. Liakoni E, Rätz Bravo AE, Krähenbühl S. Hepatotoxicity of New Oral Anticoagulants (NOACs). *Drug Saf* 2015;38:711-720.

272. Roberts PA, Bouitbir J, Bonifacio A, Singh F, Kaufmann P, Urwyler A, Krähenbühl S. Contractile function and energy metabolism of skeletal muscle in rats with secondary carnitine deficiency. *Am J Physiol Endocrinol Metab* 2015;309:E265-274.
273. Seeland S, Kettiger H, Murphy M, Treiber A, Giller J, Kiss A, Sube R, et al. ATP-induced cellular stress and mitochondrial toxicity in cells expressing purinergic P2X7 receptor. *Pharmacol Res Perspect* 2015;3:e00123.
274. Sidharta PN, Krähenbühl S, Dingemans J. Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension. *Expert Opin Drug Metab Toxicol* 2015;11:437-449.
275. Singh F, Charles AL, Schlagowski AI, Bouitbir J, Bonifacio A, Piquard F, Krähenbühl S, et al. Reductive stress impairs myoblasts mitochondrial function and triggers mitochondrial hormesis. *Biochim Biophys Acta* 2015;1853:1574-1585.
276. Taegtmeier AB, Krähenbühl S. [Drug-induced sexual dysfunction]. *Ther Umsch* 2015;72:711-715.
277. Welzenbach K, Mancuso RV, Krähenbühl S, Weitz-Schmidt G. A novel multi-parameter assay to dissect the pharmacological effects of different modes of integrin α L β 2 inhibition in whole blood. *Br J Pharmacol* 2015;172:4875-4887.
278. Ankli B, Krähenbühl S. [Gout management: an update]. *Ther Umsch* 2016;73:115-124.
279. Berger B, Donzelli M, Maseneni S, Boess F, Roth A, Krähenbühl S, Haschke M. Comparison of Liver Cell Models Using the Basel Phenotyping Cocktail. *Front Pharmacol* 2016;7:443.
280. Bloechlinger M, Ceschi A, Rüegg S, Kupferschmidt H, Kraehenbuehl S, Jick SS, Meier CR, et al. Risk of Seizures Associated with Antidepressant Use in Patients with Depressive Disorder: Follow-up Study with a Nested Case-Control Analysis Using the Clinical Practice Research Datalink. *Drug Saf* 2016;39:307-321.
281. Bonifacio A, Mullen PJ, Mityko IS, Navegantes LC, Bouitbir J, Krähenbühl S. Simvastatin induces mitochondrial dysfunction and increased atrogin-1 expression in H9c2 cardiomyocytes and mice in vivo. *Arch Toxicol* 2016;90:203-215.
282. Bouitbir J, Haegler P, Singh F, Joerin L, Felser A, Duthaler U, Krähenbühl S. Impaired Exercise Performance and Skeletal Muscle Mitochondrial Function in Rats with Secondary Carnitine Deficiency. *Front Physiol* 2016;7:345.
283. Bouitbir J, Singh F, Charles AL, Schlagowski AI, Bonifacio A, Echaniz-Laguna A, Geny B, et al. Statins Trigger Mitochondrial Reactive Oxygen Species-Induced Apoptosis in Glycolytic Skeletal Muscle. *Antioxid Redox Signal* 2016;24:84-98.
284. Brueckner D, Roesti D, Zuber UG, Schmidt R, Kraehenbuehl S, Bonkat G, Braissant O. Comparison of Tunable Diode Laser Absorption Spectroscopy and Isothermal Micro-calorimetry for Non-invasive Detection of Microbial Growth in Media Fills. *Sci Rep* 2016;6:27894.
285. Camblin M, Berger B, Haschke M, Krähenbühl S, Huwyler J, Puchkov M. CombiCap: A novel drug formulation for the basal phenotyping cocktail. *Int J Pharm* 2016;512:253-261.
286. Derungs A, Donzelli M, Berger B, Noppen C, Krähenbühl S, Haschke M. Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study. *Clin Pharmacokinet* 2016;55:79-91.
287. Juif PE, Kraehenbuehl S, Dingemans J. Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators. *Expert Opin Drug Metab Toxicol* 2016;12:879-895.
288. Krähenbühl S. [Not Available]. *Ther Umsch* 2016;73:701-706.
289. Krähenbühl S, Pavik-Mezzour I, von Eckardstein A. Unmet Needs in LDL-C Lowering: When Statins Won't Do! *Drugs* 2016;76:1175-1190.
290. Kummer O, Hammann F, Haschke M, Krähenbühl S. Reduction of hyperbilirubinemia with hypericum extract (St. John's Wort) in a patient with Crigler-Najjar syndrome type II. *Br J Clin Pharmacol* 2016;81:1002-1004.
291. Mancuso RV, Welzenbach K, Steinberger P, Krähenbühl S, Weitz-Schmidt G. Downstream effect profiles discern different mechanisms of integrin α L β 2 inhibition. *Biochem Pharmacol* 2016;119:42-55.
292. Neumair P, Joos L, Warschkow R, Dutly A, Ess S, Hitz F, Früh M, et al. Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. *Lung Cancer* 2016;100:38-44.
293. Novakova K, Kummer O, Bouitbir J, Stoffel SD, Hoerler-Koerner U, Bodmer M, Roberts P, et al. Effect of L-carnitine supplementation on the body carnitine pool, skeletal muscle energy metabolism and physical performance in male vegetarians. *Eur J Nutr* 2016;55:207-217.
294. Vogel M, Bucher P, Strasser J, Liechti ME, Krähenbühl S, Dürsteler KM. Similar and Different? Subjective Effects of Methylphenidate and Cocaine in Opioid-Maintained Patients. *J Psychoactive Drugs* 2016;48:93-100.

295. Blaser L, Hassna H, Hofmann S, Holbro A, Haschke M, Rätz Bravo A, Zeller A, et al. Leucopenia associated with metamizole: a case-control study. *Swiss Med Wkly* 2017;147:w14438.
296. Bonifacio A, Sanvee GM, Brecht K, Kratschmar DV, Odermatt A, Bouitbir J, Krähenbühl S. IGF-1 prevents simvastatin-induced myotoxicity in C2C12 myotubes. *Arch Toxicol* 2017;91:2223-2234.
297. Brecht K, Riebel V, Couttet P, Paech F, Wolf A, Chibout SD, Pognan F, et al. Mechanistic insights into selective killing of OXPPOS-dependent cancer cells by arctigenin. *Toxicol In Vitro* 2017;40:55-65.
298. Brueckner D, Krähenbühl S, Zuber U, Bonkat G, Braissant O. An alternative sterility assessment for parenteral drug products using isothermal microcalorimetry. *J Appl Microbiol* 2017;123:773-779.
299. Brueckner D, Roesti D, Zuber U, Sacher M, Duncan D, Krähenbühl S, Braissant O. Tunable diode laser absorption spectroscopy as method of choice for non-invasive and automated detection of microbial growth in media fills. *Talanta* 2017;167:21-29.
300. Brueckner D, Solokhina A, Krähenbühl S, Braissant O. A combined application of tunable diode laser absorption spectroscopy and isothermal micro-calorimetry for calorimetric analysis. *J Microbiol Methods* 2017;139:210-214.
301. Drago S, Imboden R, Schlatter P, Buylaert M, Krähenbühl S, Drewe J. Pharmacokinetics of Transdermal Etofenamate and Diclofenac in Healthy Volunteers. *Basic Clin Pharmacol Toxicol* 2017;121:423-429.
302. Duthaler U, Berger B, Erb S, Battegay M, Letang E, Gaugler S, Krähenbühl S, et al. Automated high throughput analysis of antiretroviral drugs in dried blood spots. *J Mass Spectrom* 2017;52:534-542.
303. Grünig D, Felser A, Bouitbir J, Krähenbühl S. The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells. *Toxicol In Vitro* 2017;42:337-347.
304. Haegler P, Grünig D, Berger B, Terracciano L, Krähenbühl S, Bouitbir J. Hepatic Effects of Pharmacological Doses of Hydroxy-Cobalamin[c-lactam] in Mice. *PLoS One* 2017;12:e0171026.
305. Haegler P, Joerin L, Krähenbühl S, Bouitbir J. Hepatocellular Toxicity of Imidazole and Triazole Antimycotic Agents. *Toxicol Sci* 2017;157:183-195.
306. Krähenbühl S. Importance of the skeletal muscle carnitine stores in fuel selection. *J Physiol* 2017;595:5727-5728.
307. Krähenbühl S, Pichler WJ. [Not Available]. *Ther Umsch* 2017;74:123-130.
308. Luethi D, Liechti ME, Krähenbühl S. Mechanisms of hepatocellular toxicity associated with new psychoactive synthetic cathinones. *Toxicology* 2017;387:57-66.
309. Paech F, Bouitbir J, Krähenbühl S. Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis. *Front Pharmacol* 2017;8:367.
310. Paech F, Messner S, Spickermann J, Wind M, Schmitt-Hoffmann AH, Witschi AT, Howell BA, et al. Mechanisms of hepatotoxicity associated with the monocyclic β -lactam antibiotic BAL30072. *Arch Toxicol* 2017;91:3647-3662.
311. Parra-Guillen ZP, Berger PB, Haschke M, Donzelli M, Winogradova D, Pfister B, Früh M, et al. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. *Basic Clin Pharmacol Toxicol* 2017;121:309-315.
312. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N Engl J Med* 2017;376:1713-1722.
313. Bachmann F, Duthaler U, Rudin D, Krähenbühl S, Haschke M. N-demethylation of N-methyl-4-aminoantipyrine, the main metabolite of metamizole. *Eur J Pharm Sci* 2018;120:172-180.
314. Berger B, Bachmann F, Duthaler U, Krähenbühl S, Haschke M. Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug. *Front Pharmacol* 2018;9:774.
315. Brinkman DJ, Tichelaar J, Mookink LB, Christiaens T, Likic R, Maciulaitis R, Costa J, et al. Key Learning Outcomes for Clinical Pharmacology and Therapeutics Education in Europe: A Modified Delphi Study. *Clin Pharmacol Ther* 2018;104:317-325.
316. Duthaler U, Berger B, Erb S, Battegay M, Letang E, Gaugler S, Natamatungiro A, et al. Using dried blood spots to facilitate therapeutic drug monitoring of antiretroviral drugs in resource-poor regions. *J Antimicrob Chemother* 2018;73:2729-2737.
317. Grünig D, Duthaler U, Krähenbühl S. Effect of Toxicants on Fatty Acid Metabolism in HepG2 Cells. *Front Pharmacol* 2018;9:257.
318. Grünig D, Felser A, Duthaler U, Bouitbir J, Krähenbühl S. Effect of the Catechol-O-Methyltransferase Inhibitors Tolcapone and Entacapone on Fatty Acid Metabolism in HepaRG Cells. *Toxicol Sci* 2018;164:477-488.

319. Hausherr TC, Nuss K, Thein E, Krähenbühl S, Applegate LA, Pioletti DP. Effect of temporal onsets of mechanical loading on bone formation inside a tissue engineering scaffold combined with cell therapy. *Bone Rep* 2018;8:173-179.
320. Liakoni E, Gartwyl F, Ricklin M, Exadaktylos AK, Krähenbühl S. Psychoactive substances and violent offences: A retrospective analysis of presentations to an urban emergency department in Switzerland. *PLoS One* 2018;13:e0195234.
321. Luethi D, Kaeser PJ, Brandt SD, Krähenbühl S, Hoener MC, Liechti ME. Pharmacological profile of methylphenidate-based designer drugs. *Neuropharmacology* 2018;134:133-140.
322. Luethi D, Kolaczynska KE, Docci L, Krähenbühl S, Hoener MC, Liechti ME. Pharmacological profile of mephedrone analogs and related new psychoactive substances. *Neuropharmacology* 2018;134:4-12.
323. Mingard C, Paech F, Bouitbir J, Krähenbühl S. Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines. *J Appl Toxicol* 2018;38:418-431.
324. Müller S, Nussbaumer S, Plitzko G, Ludwig R, Weinmann W, Krähenbühl S, Liakoni E. Recreational use of carfentanil - a case report with laboratory confirmation. *Clin Toxicol (Phila)* 2018;56:151-152.
325. Paech F, Abegg VF, Duthaler U, Terracciano L, Bouitbir J, Krähenbühl S. Sunitinib induces hepatocyte mitochondrial damage and apoptosis in mice. *Toxicology* 2018;409:13-23.
326. Paech F, Mingard C, Grünig D, Abegg VF, Bouitbir J, Krähenbühl S. Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells. *Toxicology* 2018;395:34-44.
327. Schöning V, Krähenbühl S, Drewe J. The hepatotoxic potential of protein kinase inhibitors predicted with Random Forest and Artificial Neural Networks. *Toxicol Lett* 2018;299:145-148.
328. Woodhead JL, Paech F, Maurer M, Engelhardt M, Schmitt-Hoffmann AH, Spickermann J, Messner S, et al. Prediction of Safety Margin and Optimization of Dosing Protocol for a Novel Antibiotic using Quantitative Systems Pharmacology Modeling. *Clin Transl Sci* 2018;11:498-505.
329. Yilmaz Y, Umehara K, Williams G, Faller T, Schiller H, Walles M, Kraehenbuehl S, et al. Assessment of the pulmonary CYP1A1 metabolism of mavoglurant (AFQ056) in rat. *Xenobiotica* 2018;48:793-803.
330. Bouitbir J, Alshaikhali A, Panajatovic MV, Abegg VF, Paech F, Krähenbühl S. Mitochondrial oxidative stress plays a critical role in the cardiotoxicity of sunitinib: Running title: Sunitinib and oxidative stress in hearts. *Toxicology* 2019;426:152281.
331. Brecht K, Kirchhofer C, Bouitbir J, Trapani F, Keiser J, Krähenbühl S. Exogenous Iron Increases Fasciocidal Activity and Hepatocellular Toxicity of the Synthetic Endoperoxides OZ78 and MT04. *Int J Mol Sci* 2019;20.
332. Bühler T, Medinger M, Bouitbir J, Krähenbühl S, Leuppi-Taegtmeyer A. Hepatotoxicity Due to Azole Antimycotic Agents in a HLA B*35:02-Positive Patient. *Front Pharmacol* 2019;10:645.
333. di Summa PG, Watfa W, Krähenbühl S, Schaffer C, Raffoul W, Bauquis O. Colic-Based Transplant in Sexual Reassignment Surgery: Functional Outcomes and Complications in 43 Consecutive Patients. *J Sex Med* 2019;16:2030-2037.
334. Docci L, Parrott N, Krähenbühl S, Fowler S. Application of New Cellular and Microphysiological Systems to Drug Metabolism Optimization and Their Positioning Respective to In Silico Tools. *SLAS Discov* 2019;24:523-536.
335. Duthaler U, Suenderhauf C, Gaugler S, Vetter B, Krähenbühl S, Hammann F. Development and validation of an LC-MS/MS method for the analysis of ivermectin in plasma, whole blood, and dried blood spots using a fully automatic extraction system. *J Pharm Biomed Anal* 2019;172:18-25.
336. Duthaler U, Suenderhauf C, Karlsson MO, Hussner J, Meyer Zu Schwabedissen H, Krähenbühl S, Hammann F. Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers. *Br J Clin Pharmacol* 2019;85:626-633.
337. Hoemme A, Barth H, Haschke M, Krähenbühl S, Strasser F, Lehner C, von Kameke A, et al. Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. *Cancer Chemother Pharmacol* 2019;83:763-774.
338. Kiene K, Hayasi N, Burhenne J, Uchitomi R, Sünderhauf C, Schmid Y, Haschke M, et al. Microdosed midazolam for the determination of cytochrome P450 3A activity: Development and clinical evaluation of a buccal film. *Eur J Pharm Sci* 2019;135:77-82.
339. Krisai P, Rudin D, Grünig D, Scherer K, Pichler W, Terracciano L, Krähenbühl S. Acute Liver Failure in a Patient Treated With Metamizole. *Front Pharmacol* 2019;10:996.
340. Leuppi-Taegtmeyer A, Duthaler U, Hammann F, Schmid Y, Dickenmann M, Amico P, Jehle AW, et al. Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions. *Nephrol Dial Transplant* 2019;34:692-702.

341. Luethi D, Hoener MC, Krähenbühl S, Liechti ME, Duthaler U. Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use. *Biochem Pharmacol* 2019;164:129-138.
342. Luethi D, Walter M, Zhou X, Rudin D, Krähenbühl S, Liechti ME. Para-Halogenation Affects Monoamine Transporter Inhibition Properties and Hepatocellular Toxicity of Amphetamines and Methcathinones. *Front Pharmacol* 2019;10:438.
343. Malagnino V, Duthaler U, Seibert I, Krähenbühl S, Meyer Zu Schwabedissen HE. OATP1B3-1B7 (LST-3TM12) Is a Drug Transporter That Affects Endoplasmic Reticulum Access and the Metabolism of Ezetimibe. *Mol Pharmacol* 2019;96:128-137.
344. Muehlan C, Fischer H, Zimmer D, Aissaoui H, Grimont J, Boss C, Croft M, et al. Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass Spectrometry. *Curr Drug Metab* 2019;20:254-265.
345. Rudin D, Lanzilotto A, Bachmann F, Housecroft CE, Constable EC, Drewe J, Haschke M, et al. Non-immunological toxicological mechanisms of metamizole-associated neutropenia in HL60 cells. *Biochem Pharmacol* 2019;163:345-356.
346. Rudin D, Roos NJ, Duthaler U, Krähenbühl S. Toxicity of metamizole on differentiating HL60 cells and human neutrophil granulocytes. *Toxicology* 2019;426:152254.
347. Rudin D, Spöndlin J, Cismaru AL, Liakoni E, Bonadies N, Amstutz U, Meier CR, et al. Metamizole-associated neutropenia: Comparison of patients with neutropenia and metamizole-tolerant patients. *Eur J Intern Med* 2019;68:36-43.
348. Sanvee GM, Bouitbir J, Krähenbühl S. Insulin prevents and reverts simvastatin-induced toxicity in C2C12 skeletal muscle cells. *Sci Rep* 2019;9:7409.
349. Sanvee GM, Panajatovic MV, Bouitbir J, Krähenbühl S. Mechanisms of insulin resistance by simvastatin in C2C12 myotubes and in mouse skeletal muscle. *Biochem Pharmacol* 2019;164:23-33.
350. Schmid Y, Navarini A, Thomas ZM, Pfeleiderer B, Krähenbühl S, Mueller SM. Sex differences in the pharmacology of itch therapies—a narrative review. *Curr Opin Pharmacol* 2019;46:122-142.
351. Singh F, Zoll J, Duthaler U, Charles AL, Panajatovic MV, Laverny G, McWilliams TG, et al. PGC-1 β modulates statin-associated myotoxicity in mice. *Arch Toxicol* 2019;93:487-504.
352. Yilmaz Y, Williams G, Manevski N, Walles M, Krähenbühl S, Camenisch G. Functional assessment of rat pulmonary flavin-containing monooxygenase activity. *Xenobiotica* 2019;49:503-512.
353. Yilmaz Y, Williams G, Walles M, Manevski N, Krähenbühl S, Camenisch G. Comparison of Rat and Human Pulmonary Metabolism Using Precision-cut Lung Slices (PCLS). *Drug Metab Lett* 2019;13:53-63.
354. Zahner C, Kruttschnitt E, Uricher J, Lissy M, Hirsch M, Nicolussi S, Krähenbühl S, et al. No Clinically Relevant Interactions of St. John's Wort Extract Ze 117 Low in Hyperforin With Cytochrome P450 Enzymes and P-glycoprotein. *Clin Pharmacol Ther* 2019;106:432-440.
355. Zhou X, Luethi D, Sanvee GM, Bouitbir J, Liechti ME, Krähenbühl S. Molecular Toxicological Mechanisms of Synthetic Cathinones on C2C12 Myoblasts. *Int J Mol Sci* 2019;20.
356. Bachmann F, Blaser L, Haschke M, Krähenbühl S, Duthaler U. Development and validation of an LC-MS/MS method for the bioanalysis of the major metamizole metabolites in human plasma. *Bioanalysis* 2020;12:175-189.
357. Bouitbir J, Alshaiikhali A, Panajatovic M, Abegg V, Paech F, Krähenbühl S. Mechanisms of Cardiotoxicity Associated with Tyrosine Kinase Inhibitors in H9c2 Cells and Mice. *Eur Cardiol* 2020;15:e33.
358. Bouitbir J, Panajatovic MV, Frechard T, Roos NJ, Krähenbühl S. Imatinib and Dasatinib Provoke Mitochondrial Dysfunction Leading to Oxidative Stress in C2C12 Myotubes and Human RD Cells. *Front Pharmacol* 2020;11:1106.
359. Bouitbir J, Sanvee GM, Panajatovic MV, Singh F, Krähenbühl S. Mechanisms of statin-associated skeletal muscle-associated symptoms. *Pharmacol Res* 2020;154:104201.
360. Cismaru AL, Rudin D, Ibañez L, Liakoni E, Bonadies N, Kreutz R, Carvajal A, et al. Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations. *Genes (Basel)* 2020;11.
361. Docci L, Klammers F, Ekiciler A, Molitor B, Umehara K, Walter I, Krähenbühl S, et al. Correction to: In Vitro to In Vivo Extrapolation of Metabolic Clearance for UGT Substrates Using Short-Term Suspension and Long-Term Co-cultured Human Hepatocytes. *Aaps j* 2020;22:142.
362. Docci L, Klammers F, Ekiciler A, Molitor B, Umehara K, Walter I, Krähenbühl S, et al. In Vitro to In Vivo Extrapolation of Metabolic Clearance for UGT Substrates Using Short-Term Suspension and Long-Term Co-cultured Human Hepatocytes. *Aaps j* 2020;22:131.
363. Docci L, Umehara K, Krähenbühl S, Fowler S, Parrott N. Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine. *Aaps j* 2020;22:128.

364. Duthaler U, Leisegang R, Karlsson MO, Krähenbühl S, Hammann F. The effect of food on the pharmacokinetics of oral ivermectin. *J Antimicrob Chemother* 2020;75:438-440.
365. Grünig D, Szabo L, Marbet M, Krähenbühl S. Valproic acid affects fatty acid and triglyceride metabolism in HepaRG cells exposed to fatty acids by different mechanisms. *Biochem Pharmacol* 2020;177:113860.
366. Krähenbühl S. [Opioid therapy in patients with liver cirrhosis]. *Ther Umsch* 2020;77:14-19.
367. Mancuso RV, Casper J, Schmidt AG, Krähenbühl S, Weitz-Schmidt G. Anti- α L β 2 antibodies reveal novel endocytotic cross-modulatory functionality. *Br J Pharmacol* 2020;177:2696-2711.
368. Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemans J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. *Expert Opin Drug Metab Toxicol* 2020;16:1063-1078.
369. Panajatovic M, Singh F, Duthaler U, Krähenbühl S, Bouitbir J. Role of PGC-1-alpha-associated Mitochondrial Biogenesis in Statin-induced Myotoxicity. *Eur Cardiol* 2020;15:e35.
370. Panajatovic MV, Singh F, Krähenbühl S, Bouitbir J. Simvastatin Impairs Glucose Homeostasis in Mice Depending on PGC-1 α Skeletal Muscle Expression. *Biomedicines* 2020;8.
371. Panajatovic MV, Singh F, Roos NJ, Duthaler U, Handschin C, Krähenbühl S, Bouitbir J. PGC-1 α plays a pivotal role in simvastatin-induced exercise impairment in mice. *Acta Physiol (Oxf)* 2020;228:e13402.
372. Roos NJ, Aliu D, Bouitbir J, Krähenbühl S. Lapatinib Activates the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 Cells. *Front Pharmacol* 2020;11:944.
373. Roos NJ, Duthaler U, Bouitbir J, Krähenbühl S. The uricosuric benzobromarone disturbs the mitochondrial redox homeostasis and activates the NRF2 signaling pathway in HepG2 cells. *Free Radic Biol Med* 2020;152:216-226.
374. Rudin D, Schmutz M, Roos NJ, Bouitbir J, Krähenbühl S. Reactive Metamizole Metabolites Enhance the Toxicity of Hemin on the ATP Pool in HL60 Cells by Inhibition of Glycolysis. *Biomedicines* 2020;8.
375. Schett A, Rothschild SI, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, et al. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC. *Cancer Chemother Pharmacol* 2020;85:121-131.
376. Suenderhauf C, Berger B, Puchkov M, Schmid Y, Müller S, Huwyler J, Haschke M, et al. Pharmacokinetics and phenotyping properties of the Basel phenotyping cocktail combination capsule in healthy male adults. *Br J Clin Pharmacol* 2020;86:352-361.
377. Zhou X, Bouitbir J, Liechti ME, Krähenbühl S, Mancuso RV. Hyperthermia Increases Neurotoxicity Associated with Novel Methcathinones. *Cells* 2020;9.
378. Zhou X, Bouitbir J, Liechti ME, Krähenbühl S, Mancuso RV. Para-Halogenation of Amphetamine and Methcathinone Increases the Mitochondrial Toxicity in Undifferentiated and Differentiated SH-SY5Y Cells. *Int J Mol Sci* 2020;21.
379. Bachmann F, Duthaler U, Krähenbühl S. Effect of deglucuronidation on the results of the Basel phenotyping cocktail. *Br J Clin Pharmacol* 2021;87:4608-4618.
380. Bachmann F, Duthaler U, Meyer Zu Schwabedissen HE, Puchkov M, Huwyler J, Haschke M, Krähenbühl S. Metamizole is a Moderate Cytochrome P450 Inducer Via the Constitutive Androstane Receptor and a Weak Inhibitor of CYP1A2. *Clin Pharmacol Ther* 2021;109:1505-1516.
381. Bachmann F, Meyer Zu Schwabedissen HE, Duthaler U, Krähenbühl S. Cytochrome P450 1A2 is the most important enzyme for hepatic metabolism of the metamizole metabolite 4-methylaminoantipyrine. *Br J Clin Pharmacol* 2022;88:1885-1896.
382. Banholzer S, Dunkelmann L, Haschke M, Derungs A, Exadaktylos A, Krähenbühl S, Liakoni E. Retrospective analysis of adverse drug reactions leading to short-term emergency hospital readmission. *Swiss Med Wkly* 2021;151:w20400.
383. Berger B, Dingemans J, Sabattini G, Delahaye S, Duthaler U, Muehlan C, Krähenbühl S. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist. *Clin Pharmacokinet* 2021;60:1349-1360.
384. Blaser LS, Duthaler U, Bouitbir J, Leuppi-Taegtmeier AB, Liakoni E, Dolf R, Mayr M, et al. Comparative Effects of Metamizole (Dipyrone) and Naproxen on Renal Function and Prostacyclin Synthesis in Salt-Depleted Healthy Subjects - A Randomized Controlled Parallel Group Study. *Front Pharmacol* 2021;12:620635.
385. Duthaler U, Weber M, Hofer L, Chaccour C, Maia M, Müller P, Krähenbühl S, et al. The pharmacokinetics and drug-drug interactions of ivermectin in *Aedes aegypti* mosquitoes. *PLoS Pathog* 2021;17:e1009382.

386. Kummer M, Müller T, Exadaktylos AK, Krähenbühl S, Liakoni E. Characteristics of Presentations to the Emergency Department Following Attempted Suicide with Drugs. *Int J Environ Res Public Health*. 2021;18:10232.
387. Leuppi-Taegtmeyer AB, Reinau D, Yilmaz S, Rüegg S, Krähenbühl S, Jick SS, Leuppi JD, et al. Antiseizure drugs and risk of developing smoking-related chronic obstructive pulmonary disease or lung cancer: A population-based case-control study. *Br J Clin Pharmacol* 2021;87:1253-1263.
388. Messner CJ, Schmidt S, Özkul D, Gaiser C, Terracciano L, Krähenbühl S, Suter-Dick L. Identification of miR-199a-5p, miR-214-3p and miR-99b-5p as Fibrosis-Specific Extracellular Biomarkers and Promoters of HSC Activation. *Int J Mol Sci* 2021;22.
389. Mueller AM, Liakoni E, Schneider C, Burkard T, Jick SS, Krähenbühl S, Meier CR, et al. The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study. *J Gen Intern Med* 2021;36:2639-2647.
390. Panajatovic MV, Singh F, Krähenbühl S, Bouitbir J. Effects of Simvastatin on Lipid Metabolism in Wild-Type Mice and Mice with Muscle PGC-1 α Overexpression. *Int J Mol Sci* 2021;22.
391. Sanvee GM, Bouitbir J, Krähenbühl S. C2C12 myoblasts are more sensitive to the toxic effects of simvastatin than myotubes and show impaired proliferation and myotube formation. *Biochem Pharmacol* 2021;190:114649.
392. Sanvee GM, Hitzfeld L, Bouitbir J, Krähenbühl S. mTORC2 is an important target for simvastatin-associated toxicity in C2C12 cells and mouse skeletal muscle - Roles of Rap1 geranylgeranylation and mitochondrial dysfunction. *Biochem Pharmacol* 2021;192:114750.
393. Schittny A, Waldner S, Duthaler U, Vorobyev A, Abramovich R, Krähenbühl S, Puchkov M, et al. Particle Forming Amorphous Solid Dispersions: A Mechanistic Randomized Pharmacokinetic Study in Humans. *Pharmaceutics* 2021;13.
394. Scholz I, Liakoni E, Hammann F, Grafinger KE, Duthaler U, Nagler M, Krähenbühl S, et al. Effects of *Hypericum perforatum* (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. *Br J Clin Pharmacol* 2021;87:1466-1474.
395. Vischer AS, Kuster GM, Twerenbold R, Pfister O, Zhou Q, Villiger A, Poglitsch M, et al. Influence of Antihypertensive Treatment on RAAS Peptides in Newly Diagnosed Hypertensive Patients. *Cells* 2021;10.
396. Witzigmann D, Grossen P, Quintavalle C, Lanzafame M, Schenk SH, Tran XT, Englinger B, et al. Non-viral gene delivery of the oncotoxic protein NS1 for treatment of hepatocellular carcinoma. *J Control Release* 2021;334:138-152.
397. Kasenda B, König D, Manni M, Ritschard R, Duthaler U, Bartoszek E, Bärenwaldt A, et al. Targeting immunoliposomes to EGFR-positive glioblastoma. *ESMO Open* 2022;7:100365.
398. Docci L, Milani N, Ramp T, Romeo AA, Godoy P, Franyuti DO, Krähenbühl S, Gertz M, Galetin A, Parrott N, Fowler S. Exploration and application of a liver-on-a-chip device in combination with modelling and simulation for quantitative drug metabolism studies. *Lab Chip*. 2022;22:1187-1205.
399. Roos NJ, Mancuso RV, Sanvee GM, Bouitbir J, Krähenbühl S. Imatinib disturbs lysosomal function and morphology and impairs the activity of mTORC1 in human hepatocyte cell lines. *Food Chem Toxicol*. 2022;162:112869.
400. Bouitbir J, Panajatovic MV, Krähenbühl S. Mitochondrial Toxicity Associated with Imatinib and Sorafenib in Isolated Rat Heart Fibers and the Cardiomyoblast H9c2 Cell Line. *Int J Mol Sci*. 2022;23:2282.
401. Duthaler U, Bachmann F, Suenderhauf C, Grandinetti T, Pfefferkorn F, Haschke M, Hruz P, Bouitbir J, Krähenbühl S. Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently. *Clin Pharmacokinet*. 2022;61:1039-1055.
402. Novakova K, Török M, Panajatovic M, Bouitbir J, Duong FHT, Handschin C, Krähenbühl S. PGC-1 α and MEF2 Regulate the Transcription of the Carnitine Transporter OCTN2 Gene in C2C12 Cells and in Mouse Skeletal Muscle. *Int J Mol Sci*. 2022;23:12304.
403. Krähenbühl L, Krähenbühl S. Rats with Long-Term Cholestasis Have a Decreased Cytosolic but Maintained Mitochondrial Hepatic CoA Pool. *Int J Mol Sci*. 2023;24:4365.
404. Mancuso RV, Schneider G, Hürzeler M, Gut M, Zurflüh J, Breitenstein W, Bouitbir J, Reisen F, Atz K, Ehrhardt C, Duthaler U, Gyax D, Schmidt AG, Krähenbühl S, Weitz-Schmidt G. Allosteric targeting resolves limitations of earlier LFA-1 directed modalities. *Biochem Pharmacol*. 2023;211:115504.
405. Ozbey AC, Bachmann F, Duthaler U, Annaert P, Fowler S, Umehara K, Parrott N, Krähenbühl S. Dose Adjustment in Patients with Liver Cirrhosis - Comparison of Two Different Modeling Approaches. *Clin Pharmacol Ther*. 2023;113:1346-1358.
406. Duthaler U, Bachmann F, Ozbey AC, Umehara K, Parrott N, Fowler S, Krähenbühl S. The Activity of Members of the UDP-Glucuronosyltransferase Subfamilies UGT1A and UGT2B is Impaired in Patients with Liver Cirrhosis. *Clin Pharmacokinet*. 2023;62:1141-1155.

407. Abegg VF, Panajatovic MV, Mancuso RV, Allard JA, Duthaler U, Odermatt A, Krähenbühl S, Bouitbir J. Mechanisms of hepatocellular toxicity associated with the components of St. John's Wort extract hypericin and hyperforin in HepG2 and HepaRG cells. *Toxicol Lett.* 2024 Jan 14;393:1-13.
408. Sudano I, Krähenbühl S, Mach F, Anstett A, Dhalwani N, Bridges I, Sibartie M, Ray KK. Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study. *Ther Adv Cardiovasc Dis.* 2024;18:17539447231213288
409. Ozbey AC, Keemink J, Wagner B, Pugliano A, Krähenbühl S, Annaert P, Fowler S, Parrott N, Umehara K. Physiologically Based Pharmacokinetic Modeling to Predict the Impact of Liver Cirrhosis on Glucuronidation via UGT1A4 and UGT2B7/2B4-A Case Study with Midazolam. *Drug Metab Dispos* 2024;52:614-625
- 410: Duthaler U, Chapuisat F, Hanimann R, Krähenbühl S. Effect of protein binding on the pharmacokinetics of the six substrates in the Basel phenotyping cocktail in healthy subjects and patients with liver cirrhosis. *Eur J Pharm Sci.* 2024;202:106885.

Articles not in PubMed (not peer-reviewed)

1. Krähenbühl S. Pharmakokinetische und pharmakodynamische Besonderheiten im Alter: Bedeutung für die Therapie mit Psychopharmaka. *Moderne Geriatrie* 1994;10:218-228.
2. Krähenbühl S. Pharmakokinetische und dynamische Besonderheiten der medikamentösen Therapie in der Geriatrie. *Geriatrie Praxis* 1995;6:33-39.
3. Krähenbühl S. Welche Analgetika wann einsetzen ? *Medical Tribune* 1996;Suppl17:20-23.
4. Krähenbühl S, Reichen J. Prescribing in patients with liver cirrhosis. *Medicine* 1998;26:23-26.
5. Krähenbühl S. Medikamentendosierung bei Patienten mit Nieren- oder Leberinsuffizienz. *Moderne Geriatrie* 1999;10:26-33.
6. Krähenbühl S. Pharmakotherapie bei älteren Patienten: Problematik und Lösungsstrategien. *Medical Tribune.* 2000; 20 (Suppl):10-12.
7. Krähenbühl S. L-carnitine and vegetarianism. *Ann Nutr Metab* 2000;44:81-82.
8. Krähenbühl S. L-carnitine and physical performance. *Ann Nutr Metab* 2000;44:84-86.
9. Krähenbühl S. Cytochrom P450 oder Plasmaproteine: Klinische Bedeutung für unerwünschte Arzneimittelinteraktionen. *Klinikerarzt* 2001;30:54-58.
10. Eich G, Krähenbühl S, Flückiger U. Nasalflu Berna: intranasaler, inaktivierter Grippeimpfstoff. *Forum Med Suisse* 2001;1:260-262.
11. Krähenbühl S. Therapie der arteriellen Hypertonie bei älteren Patienten. *Geriatrie Praxis* 2001;12:29-33.
12. Krähenbühl S, Reichen J. Prescribing in patients with liver cirrhosis. *Medicine* 2002;30:24-27.
13. Krähenbühl S. Dosisangleichung bei Niereninsuffizienz und Nierenersatzverfahren. *Eur J Hosp Pharmacy* 2004;10:24-27
14. Egger SS, Schlienger RG, Krähenbühl S. Vorgehen bei unerwünschten Arzneimittelwirkungen. *Schweiz Med Forum* 2005;5:292-6
15. Krähenbühl S. Arzneimittelinteraktionen mit Statinen. *Med.Pharm.Drog.Hosp.* 2005;4:5-8.
16. Egger SS, Krähenbühl S, Schlienger R. Umgang mit unerwünschten Arzneimittelwirkungen in der zahnärztlichen Praxis. *Schweiz Monatsschr Zahnmed* 2005;115:1209-1213
17. Todesco L, Waldhauser K, Krähenbühl S. Mitochondrial toxicity of drugs. *Chimia* 2006;60:37-39
18. Lampert ML, Krähenbühl S, Hersberger K, Schlienger RG. Clinical pharmacy and pharmaceutical care: patient-oriented application of pharmaceutical expertise. *Chimia* 2006;60:58-61
19. Krähenbühl S. Mit Mangelernährung assoziierte Medikamente: ein Problem im Alter? *Schweizer Zeitschrift für Ernährungsmedizin* 2006;5:22-27
20. Krähenbühl S. Therapie mit Opiaten bei geriatrischen Patienten. *Geriatrie Praxis* 2007;1:18-24.
21. Kummer O, Krähenbühl S, Haschke M. Generika in der Praxis: kleine aber beachtenswerte Unterschiede. *medArt* 2007;17-19.
22. Krähenbühl S. Pharmakotherapie in den letzten 40 Jahren: Rückblick und Ausblick. *Medical Tribune* 2007;40(26):24-27
23. Blöchliger M, Zbinden-Scheurer G, Gasser B, Krähenbühl S, Stötter H. Dosierungsempfehlungen für Kinder in der Arzneimittelinformation. *Pädiatrie* 2009;15:19-21.
24. Gasser B, Krähenbühl S, Riedl J, Stötter H. Rezepturherstellungen für die pädiatrische Anwendung. *Pädiatrie* 2009;15:22-24.

25. Graf M, Krähenbühl S, Stötter H. Vergleich pädiatrischer Dosierungsempfehlungen aus verschiedenen Quellen. *Pädiatrie* 2009;15:25-27.
26. Krähenbühl S. L-Carnitin als Nahrungsmittelergänzung. *Schweiz Zschr Ernährungsmed* 2010;10:46-50.
27. Derungs A, Krähenbühl S. Xerostomie, Gingivahyperplasie, Kiefernekrose. Wie Medikamente auf den Mund wirken. *Zahnarzt PR XIS* 2010;3-4:31-34.
28. Derungs A, Krähenbühl S. Xerostomie, Gingivahyperplasie, Kiefernekrose. Wie Medikamente auf den Mund wirken. *Hausarzt PRAXIS* 2010;15:14-17.
29. Bruggisser M, Taegtmeyer A, Ruppen W, Krähenbühl S, Haschke M. AV-Block III und mechanische Reanimation nach Anästhesieeinleitung mit Propofol und Fentanyl. *Schweiz Med Forum* 2010;10:657–658.
30. Wuillemin WA, Krähenbühl S. Hohe Ferritinwerte nach Eiseninfusion – gefährlich? *Swiss Medical Forum* 2010;10:844-846
31. Krähenbühl S. Polypharmazie im Alter: Chance und Risiken. *Der Informierte Arzt (Geriatric Forum)* 2012;4:38-41.
32. Krähenbühl S. Korrekte Einnahme von Medikamenten. *Der Informierte Arzt* 2021;(12):24-26
33. Krähenbühl S. Relevante Arzneistoffinteraktionen bei der Behandlung der Herzinsuffizienz und der Hypertonie. *Der Informierte Arzt*. 2024;(2): 25-29.

Book chapters

1. Reichen J, Krähenbühl S, Wirth HP, Maier KP. Liver function in cholestatic liver disease: a critical appraisal. In: *Bile acids and the hepatobiliary system: from basic science to clinical practice*. 68th Falk Symposium. Paumgartner G, Stiehl A, Gerok W, editors. Dordrecht: Kluwer. 1993; 258-270.
2. Reichen J, Krähenbühl S, Zimmermann H. Impact of cholestasis on hepatic function: retention of cholephiles and their potential targets. In: *Cholestasis*. Excerpta Medica. Gentilini P, Arias IM, McIntyre N, Rodés J, editors. Elsevier Science B.V. 1994;167-175.
3. Krähenbühl S, Follath F. Pharmakotherapie im Alter. In: *Grundlagen der Arzneimitteltherapie*. Documed AG, Basel. 1996;168-171.
4. Krähenbühl S, Meier C, Krähenbühl A, Meier-Abt PJ. Unerwünschte Wirkungen von Arzneimitteln. In: *Grundlagen der Arzneimitteltherapie*. Documed AG, Basel. 1996;39-104.
5. Krähenbühl S, Kaplowitz N. Drug-induced hepatotoxicity. In: *Acute and chronic liver diseases: Molecular biology and clinics*. Schmid R, Bianchi L, Blum HE, Gerok W, Maier KP, Stalder GA, editors. Kluwer Academic Publishers 1996;147-158.
6. Krähenbühl S, Krähenbühl L. Mitochondrial dysfunction associated with chronic cholestasis. In: *Cholestatic liver disease*. 102th Falk Symposium. Manns MP, Boyer JL, Jansen PLM, Reichen J, editors. Dordrecht: Kluwer. 1998;107-116.
7. Krähenbühl S. Patienten mit Organerkrankungen. In: *Lehrbuch der Klinischen Pharmakologie*. Jaehde U, Radziwill R, Mühlebach S, Schunack W, editors. Stuttgart: Wissenschaftliche Verlagsgesellschaft. 1998;297-310.
8. Krähenbühl S, Mühlebach S. Variabilität der Arzneimitteltherapie. In: *Lehrbuch der Klinischen Pharmakologie*. Jaehde U, Radziwill R, Mühlebach S, Schunack W, editors. Stuttgart: Wissenschaftliche Verlagsgesellschaft. 1998;141-145.
9. Krähenbühl S, Reichen J. Drug hepatotoxicity. In: *Liver disease. Diagnosis and Management*. Bacon BR, Di Bisceglie AM, editors. New York, Edinburgh, London. Churchill Livingstone. 2000;294-309.
10. Krähenbühl-Melcher A, Schlienger R, Krähenbühl S. Unerwünschte Wirkungen von Medikamenten. In: *Grundlagen der Arzneimitteltherapie*. Documed AG, Basel. 2001;58-135.
11. Krähenbühl S, Follath F. Pharmakotherapie im Alter. In: *Grundlagen der Arzneimitteltherapie*. Documed AG, Basel. 2001;235-41.
12. Krähenbühl S. Pathophysiologie der Gallensekretion und Motilität der Gallenwege. In: *Viszeralchirurgie*. Siewert, Harder, Rothmund, editors. Springer Verlag. 2002;641-645.
13. Krähenbühl S. Pharmakokinetische Prinzipien und Dosisanpassung. In: *Medizinische Therapie in Klinik und Praxis*. J. Schölmerich. Springer-Verlag. 2003;25-33.

14. Krähenbühl S. Adverse effects and drug-drug interactions. In: Pharmacotherapy of obesity. Hofbauer KG, Keller U, Boss O, editors. CRC Press. 2004;285-296.
15. Wenk M, Drewe J, Krähenbühl S. Abteilung für Klinische Pharmakologie & Toxikologie am Universitätsspital Basel. Philippu A, editor. Geschichte und Wirken der pharmakologischen, klinisch-pharmakologischen und toxikologischen Institute im deutschsprachigen Raum. Berenkamp. 2004;40-46.
16. Krähenbühl S. Pharmakokinetische Prinzipien und Dosisanpassung. In: Medizinische Therapie in Klinik und Praxis. J. Schölmerich. 2. Auflage. Springer Verlag. 2005;23-30.
17. Schlatter C, Krähenbühl S. Dosisanpassung bei Leberkrankheiten. In: Grundlagen der Arzneimitteltherapie. Documed AG, Basel. 2005;6-13.
18. Egger SS, Schlienger RG, Krähenbühl S, Stoller R, Fattinger K. Unerwünschte Wirkungen von Arzneistoffen. In: Grundlagen der Arzneimitteltherapie. Documed AG, Basel. 2005;54-148.
19. Drewe J, Krähenbühl S. Klinisch relevante Entzugssyndrome. In: Grundlagen der Arzneimitteltherapie. Documed AG, Basel. 2005;244-7.
20. Krähenbühl S, Follath F. Pharmakotherapie im Alter. In: Grundlagen der Arzneimitteltherapie. Documed AG, Basel. 2005;269-73.
21. Krähenbühl S. Pharmakokinetische Prinzipien und Dosisanpassung. In: Medizinische Therapie. J. Schölmerich. 3. Auflage. Springer-Verlag. 2007;25-33